Medical device regulatory changes, tracked

What changed for medical devices across markets, who it affects, what to do, and the dates that matter. Every entry is checked against the authority's own instrument before it appears here, and each one links to that instrument.

Updated 4 Nov 2026 · 184 changes since Jan 2025 · 30+ markets

Coming up in the next 12 months

South Korea
Open for comment
Comments close: 16 Nov 2026

South Korea: proposal to accept WHO prequalification clinical data for IVD approval

MFDS proposes amending its IVD approval, certification and notification regulation (MFDS Notification 2026-58). Clinical performance data that WHO accepted during prequalification, or that informed a WHO prequalification listing, would count towards a Korean approval for reagents and instruments. An application rejected only for missing clinical performance data and refiled within two years would be reviewed on the new data alone. For foreign documents in a language other than English, a full translation certified by the manufacturer would replace a notarized one, as devices have had since April 2026. Class 1 IVD instruments filed by notification could leave out raw materials, and the exemption from the sales-business notification would cover any IVD designated for a public health crisis, not only COVID-19 self-tests. Comments are due by 16 November 2026. The amendment would take effect on the day it is issued; applications already filed stay under the current rules.

What to do. If you hold a WHO prequalification or file Korean dossiers with non-English documents, read the draft and comment to MFDS by 16 November.

IVDReliance & recognitionClinical evidence & trialsRegistration route
Sources (1) · verified against the instrument 1 Nov 2026
United States
Open for comment
Comments close: 17 Nov 2026

United States: draft guidance would move PMAs onto the eSTAR electronic template

A draft guidance announced on 18 September 2026 introduces the electronic submission template for original PMAs, panel-track, 180-day and real-time supplements, and 30-day notices and 135-day supplements. When final, it will set the timetable from which these submissions must be filed electronically in that format, as FDA already requires for De Novo requests. Comments are due by 17 November 2026.

What to do. If a PMA or PMA supplement is planned for 2027, comment on the timetable by 17 November and start building the dossier in the template.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
United States
Open for comment
Comments close: 24 Nov 2026

United States: FDA draft guidance on premarket submissions for robotically-assisted surgical devices

FDA published draft recommendations for premarket submissions for robotically-assisted surgical devices. It is a draft, not for implementation. Comments are due by 24 November 2026.

What to do. If you develop a surgical robot, read the draft against your planned submission and comment by 24 November.

Active (powered)Registration route
Sources (1) · verified against the instrument 19 Oct 2026
European Union
In force
Deadline: 27 Nov 2026

European Union: EUDAMED is mandatory, and devices already on the market must be registered by 27 November 2026

Commission Decision (EU) 2025/2371, published on 27 November 2025, declared four EUDAMED modules functional: actor registration, UDI/device registration, notified bodies and certificates, and market surveillance. Under Regulation (EU) 2024/1860 they became mandatory 6 months later, on 28 May 2026. Devices still being placed on the market after that date, including legacy devices under the MDR transitional provisions, must be in the UDI/device module within 12 months of the notice, which by our count is 27 November 2026. The vigilance and clinical-investigation modules are not yet mandatory.

What to do. Count the Basic UDI-DIs you still place on the EU market and finish the device registrations before 27 November 2026; non-EU makers need actor registration through their authorized representative first.

All devicesAdministrativeLabeling
Sources (2) · verified against the instrument 20 Oct 2026
Canada
Final — not yet in force
Starts: 1 Dec 2026

Canada: establishment-license holders must name their suppliers from December 2026

SOR/2026-110 requires applicants for a medical device establishment license to give the name and address of each supplier that is not a manufacturer and the device classes it supplies, and to update the list at the annual review. Importers no longer have to buy from foreign distributors that hold a license. The regulation takes effect on the 180th day after its registration on 4 June 2026, which by our count is 1 December 2026; Health Canada's bulletin gives 14 December. A pending application cannot be granted unless the supplier information was filed by that day.

What to do. If you sell through a distributor into Canada, expect your importer to name it to Health Canada, and plan for 1 December, the earlier of the two dates.

All devicesImport & licensing
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
South Korea
Final — not yet in force
Starts: 10 Dec 2026

South Korea: a designated emergency-import list for devices, imported by NIDS, from 10 December 2026

Article 15-2 of the Medical Devices Act already let MFDS supply urgently needed devices, including any that the head of a relevant central government agency requests, without an import license. The amendment of 9 June 2026, in force on 10 December 2026, makes MFDS designate each device as an emergency-import device, run a demand survey and a supply plan first, and lets it withdraw a designation. It names the Korea National Institute of Medical Device Safety Information (NIDS) as the importer.

What to do. If a Korean ministry wants your unapproved device, the route runs through an MFDS designation and NIDS, not a license in your name. Keep your own registration plan separate.

All devicesImport & licensingSupply & shortages
Sources (1) · verified against the instrument 2 Nov 2026
South Korea
Final — not yet in force
Starts: 10 Dec 2026

South Korea: ask MFDS whether a product is a device, and no AI-generated expert endorsements, from 10 December 2026

An amendment to the Medical Devices Act takes effect on 10 December 2026. Anyone planning an application or clinical trial can ask MFDS for a pre-review of whether a product is a medical device and what class it falls in. Advertising that uses AI-generated images, voices or video that could make people think a doctor or other expert recommends the device is banned. The 'rare and emergency introduction' category is renamed 'emergency introduction devices', with rules on designation and supply planning. A draft Enforcement Rule setting the pre-review fee was published for consultation on 14 September 2026.

What to do. If your software sits near the device boundary in Korea, plan to use the new pre-review once it opens, and check any AI-generated advertising.

All devicesSoftware & AIClassificationSoftware & AI rules
Sources (2) · verified against the instrument 20 Oct 2026
Brazil
Open for comment
Comments close: 11 Dec 2026

Brazil: ANVISA consults on a regulatory sandbox for innovative products

ANVISA's draft RDC would set up a regulatory sandbox: a supervised, time-limited setting in which innovative products, services and business models under its control can be tested where current rules make it impossible to gather the evidence needed. The draft covers governance, selection criteria, temporary authorization, monitoring and safeguards. It is not specific to devices. Comments are open from 13 October to 11 December 2026.

What to do. If current Brazilian rules block your product (for example, novel software), comment by 11 December 2026 and watch for the first call for projects.

All devicesSoftware & AIRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
Switzerland
In force
Deadline: 31 Dec 2026

Switzerland: devices must be registered in swissdamed, with a transition to 31 December 2026

Since 1 July 2026, manufacturers and their Swiss authorized representatives must register devices, systems and procedure packs placed on the Swiss market in the swissdamed UDI Devices module. The transition period runs to 31 December 2026, but devices with a serious incident, field safety corrective action or trend report must be registered at once. Registration replaces the old notification for Class I devices and IVDs. Swissmedic will charge CHF 200 for the first UDI-DI and CHF 20 for each further UDI-DI on the market, capped at CHF 10,000 a year, invoiced from January 2027.

What to do. Have your CH-REP register every device before 31 December 2026 and budget the per-UDI-DI fee.

All devicesAdministrativeFees
Sources (2) · verified against the instrument 20 Oct 2026
Singapore
In force
Deadline: 31 Dec 2026

Singapore: HSA waives evaluation fees to move clinically needed devices off special access

HSA will waive evaluation fees for eligible devices now supplied through the Special Access Route, so they can be formally registered. It is aimed at devices for small patient populations with limited commercial viability in Singapore. A clinician starts the process with a Clinical Justification and Endorsement Form and the supplier files. The first window closes 31 December 2026; after that it opens every year from 1 October to 31 December.

What to do. If your device reaches Singapore patients through special access, ask the clinicians who use it to endorse it before 31 December.

All devicesFeesRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
Israel
In force
Deadline: 31 Dec 2026

Israel: the pilot accepting MDR certificates from notified bodies in non-recognized countries runs to 31 December 2026

The Health Ministry's medical device division (AMAR) extended its pilot that accepts, for registration in the Israeli medical device register, EU MDR CE certificates issued by notified bodies that the EU designated under the MDR but that sit in countries Israel's Medical Equipment Law does not recognize. The pilot now runs to 31 December 2026, after which the ministry will review its policy in light of the results.

What to do. If your CE certificate comes from such a notified body, file in Israel before 31 December 2026, or plan for the policy to change after that date.

All devicesReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
Deadline: 31 Dec 2026

China: public hospitals to buy medical equipment through central tenders

A National Health Commission notice (Guoweicaiwuhan [2026] No. 131, 20 May 2026) requires public health institutions to buy equipment on the departmental catalogs through central procurement, in principle by open tender. NHC buys Class A large equipment nationally; provinces buy Class B large equipment and other high-spend equipment with little competition, with at least one round by the end of 2026 and one each first half-year after; each province must pilot city-level central buying by the end of June 2027. Bids are judged on quality, price and service, including lifetime costs of consumables and maintenance, and prices go into a national database.

What to do. If you sell capital equipment to Chinese public hospitals, plan for provincial tender rounds and lifetime-cost scoring.

Active (powered)HTA & reimbursement
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
Deadline: 1 Jan 2027

China: NGS reagents classified, with Class I filings that do not fit to be registered by 1 January 2027

NMPA Notice 2025 No. 22 (9 June 2025) issues a classification guideline for next-generation sequencing IVD reagents. Sequencing reagents and library-preparation reagents are encouraged to register together as a Class III IVD; if filed separately, each must name the other or the registered sequencer it works with. NGS reagents already filed as Class I that the guideline says are not Class I must be registered; from 1 January 2027 they cannot be made, imported or sold without a registration certificate.

What to do. If you sell NGS reagents in China under a Class I filing, check them against the guideline now and start the registration.

IVDClassification
Sources (1) · verified against the instrument 20 Oct 2026
United States
Open for comment
Comments close: 28 Jan 2027

United States: FDA revises its draft guidance on drug-delivery performance data for drug delivery devices and combination products

FDA published a revised draft guidance on the drug-delivery performance information to submit for devices, and for combination products with a device constituent part, that deliver a drug or biological product. It replaces the July 2024 draft "Essential Drug Delivery Outputs", clarifies how drug-delivery performance should be tested and controlled, and aligns the text with the revised Quality Management System Regulation (21 CFR part 820). It covers investigational, marketing and post-market change applications. It is a draft and not binding; comments are due by 28 January 2027 under docket FDA-2024-D-2560.

What to do. If you make a device that delivers a drug or biologic, or the device part of a combination product, compare your performance testing and controls with the revised draft and comment by 28 January 2027.

CombinationActive (powered)Non-activeRegistration routeQMS & GMP
Sources (1) · verified against the instrument 1 Nov 2026
Brazil
Open for comment
Comments close: 28 Jan 2027

Brazil: ANVISA consults on reprocessing rules and on how a device is designated single-use or reusable

ANVISA opened four linked consultations on reprocessing medical devices. One (CP 1.423) proposes rules on whether a device is designated single-use or reusable and how it is registered; that one comes from the device-products area and affects manufacturers' labeling and registration. The other three cover reprocessing in hospitals, in reprocessing companies, and the validation of reprocessing protocols. Comments run from 1 October 2026 to 28 January 2027.

What to do. If you sell single-use or reusable devices in Brazil, read CP 1.423 and comment by 28 January 2027.

All devicesLabelingPost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
Canada
Final — not yet in force
Starts: 1 Feb 2027

Canada: new forms for the medical-device Special Access Program, mandatory from 1 February 2027

Health Canada's notice of 24 August 2026 introduces a new application form, a spreadsheet template and a secure transmission tool for the Special Access Program for devices. From 1 February 2027 it will accept only applications made this way.

What to do. Replace the old forms and links in any clinician-facing material before 1 February 2027.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
India
In force
Deadline: 14 Feb 2027

India: devices sterilised at another licensed site must show that site's license number on the label

G.S.R. 743(E), the Medical Devices (Second Amendment) Rules 2026, adds a labeling rule. A manufacturer that outsources sterilisation to another site licensed for it must print that site's license number on the label, mandatory six months from the notification dated 14 August 2026 (by our count, 14 February 2027). CDSCO had told states in June 2025 that no loan license is needed for such outsourcing. The same rules add a Ninth Schedule of fees for tests by government device-testing laboratories, rising 5% a year.

What to do. If you outsource sterilisation for devices sold in India, change your labels before February 2027.

All devicesLabelingFeesQMS & GMP
Sources (2) · verified against the instrument 20 Oct 2026
South Korea
Final — not yet in force
Starts: 16 Mar 2027

South Korea: a ban on brokering sales of unapproved devices, and online advertising monitoring

An amendment to the Medical Devices Act promulgated on 15 September 2026 bans brokering the sale or rental of devices that have not been approved, certified or notified, and lets MFDS monitor illegal device labeling and advertising online. It also lets MFDS ask the Korea Customs Service for import declaration data on devices. The amendment takes effect on 16 March 2027; one provision, Article 32-3, took effect on promulgation.

What to do. If you sell through Korean online platforms or agents, make sure every listing points to a product with a valid Korean license.

All devicesPost-market & vigilanceImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
Japan
Open for comment
Comments close: 17 Mar 2027

Japan: PMDA draft review points for generative-AI medical devices

PMDA published draft review points (dated 14 September 2026; English translation 14 October) for devices built on large language or vision-language models: a total life-cycle approach, a narrow intended use first, post-market reporting of hallucinations and adverse events, and monitoring of agent-like functions. Not binding. Comments are open until 17 March 2027.

What to do. If you build a generative-AI device, read the draft, plan Japanese-language evaluation, and comment by 17 March 2027.

Software & AISoftware & AI rules
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
Chile
Final — not yet in force
Starts: 25 Mar 2027

Chile: blood-donor screening tests need registration from 25 March 2027

Exempt Decree 31 (signed 6 March, published 24 March 2026) brings serological tests used to screen blood donations under ISP's mandatory control: tests for Chagas, syphilis, hepatitis B, hepatitis C and HTLV I/II. They are Class D, verified against NCh-ISO 16142-2:2021, and each product needs an ISP first-lot evaluation with at least 95% specificity and 100% sensitivity. Rapid tests are outside its scope, because they are not recommended for screening donations. Products that ISP has already evaluated for sensitivity and specificity do not repeat that evaluation if they meet the decree's thresholds. The decree takes effect 12 months after publication, which Ley Chile records as 25 March 2027.

What to do. If you supply donor-screening assays in Chile, plan conformity verification and ISP's first-lot evaluation before March 2027.

IVDRegistration routeClassification
Sources (1) · verified against the instrument 27 Oct 2026
United Kingdom
Comment period closed
Starts: 1 Apr 2027

Great Britain: MHRA proposes raising the annual device fee from £300 to £511 per category from April 2027

The MHRA consulted from 17 August to 25 September 2026 on fees from 1 April 2027. For devices it proposes £511 instead of £300 per chargeable GMDN Level 2 category, still part-subsidised for 2027/28 and 2028/29, a device regulatory advice meeting at £2,245 instead of £987, most other fees up 8.93%, and fee waivers for eligible UK-based SMEs. No government response has been published yet.

What to do. Budget £511 per chargeable category for 2027/28 until the government response confirms the figure.

All devicesFees
Sources (2) · verified against the instrument 20 Oct 2026
Indonesia
In force
Deadline: 4 May 2027

Indonesia: a new health-supplies regulation replaces the 2017 device registration rule

Permenkes 5/2026 on health supplies (promulgated 4 May 2026, in force that day) revokes Permenkes 62/2017 on device marketing authorization, along with the 2014 special-access, 2017 import-supervision and other device regulations. Existing implementing rules stay in force where they do not conflict, and the sector has one year to adjust, to 4 May 2027 by our count. Marketing-authorization holders must report a potential shortage at least six months ahead. The regulation also allows faster authorization for innovative products used in other countries, but leaves the details to a ministerial guideline not yet issued.

What to do. Ask your Indonesian license holder whether your next filing or renewal follows any new requirement, and set up the six-month shortage notice.

All devicesIVDRegistration routeImport & licensingSupply & shortages
Sources (1) · verified against the instrument 20 Oct 2026
Mexico
Final — not yet in force
Starts: 14 May 2027

Mexico: a new device labeling standard, with a visible version identifier for software

NOM-137-SSA1-2025 (published 19 May 2026) replaces the 2008 labeling standard and takes effect 360 calendar days after publication, 14 May 2027 by our count. Software as a medical device must carry an identifier (version, revision or release date) the user can see; software with no physical form may be labeled electronically; labels must be in Spanish and match the registration.

What to do. Schedule the new standard into your next label revision; for software, show the version in the product and link to the labeling from inside it.

All devicesSoftware & AILabelingSoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Japan
Final — not yet in force
Starts: 20 May 2027

Japan: from 20 May 2027 regulators can order an officer replaced, and designated IVDs must be re-evaluated

A Cabinet Order fixed 20 May 2027 for the last main tranche of the 2025 PMD Act amendment that touches devices. From that date MHLW can order a device marketing authorization holder or manufacturer to replace the officer responsible for regulatory affairs where a breach of pharmaceutical law cannot otherwise be put right. Holders of IVD approvals must also undergo a performance re-evaluation when MHLW, after hearing the Pharmaceutical Affairs Council, designates a range of IVDs for it. The amendment's other device changes, including conditional approval and shortage priority review, took effect on 1 May 2026.

What to do. Make sure your Japanese partner's governance names the responsible officers, and watch for MHLW designating your IVD category for re-evaluation.

All devicesIVDPost-market & vigilanceAdministrative
Sources (2) · verified against the instrument 20 Oct 2026
South Africa
In force
Deadline: 1 Jun 2027

South Africa: ISO 13485 certification becomes a condition of device establishment licenses, in phases to 2028

SAHPRA requires manufacturers and distributors (importers) holding a medical device establishment license to hold ISO 13485 certification from a conformity assessment body SAHPRA recognizes, in the name and at the address of the South African establishment. It applies to license renewals from 1 June 2025, to holders already certified (who are asked to submit the certificate) from 1 April 2026, to license amendments and product-list notifications from 1 June 2027, and to all new license applications from 1 April 2028. Product registration of devices has still not been called up, so the establishment license remains the main control.

What to do. Check that your South African importer holds, or is working towards, ISO 13485 from a SAHPRA-recognized body; an importer that cannot renew its license cannot import your product.

All devicesIVDQMS & GMPImport & licensing
Sources (3) · verified against the instrument 20 Oct 2026
China
Final — not yet in force
Deadline: 1 Jun 2027

China: UDI extends to every Class II device from June 2027 and every Class I device from June 2029

NMPA, the National Health Commission and the National Healthcare Security Administration (Announcement 2026 No. 21, 4 March 2026) extend UDI beyond Class III and the 103 Class II types already covered. All Class II devices, including IVDs, and all Class I IVDs made from 1 June 2027 must carry a UDI; all Class I devices made from 1 June 2029. Product identifiers go into the registration or filing system for new applications from those dates, and into existing files at renewal or change. Data must be uploaded to the UDI database before sale and, where a device has a health-insurance code, linked to it.

What to do. If you have Class I or II devices in China, plan labeling and database uploads now for products made from 1 June 2027.

All devicesIVDLabeling
Sources (1) · verified against the instrument 20 Oct 2026
Canada
Final — not yet in force
Starts: 17 Jun 2027

Canada: amended device shortage and discontinuation reporting starts 17 June 2027

Guide GUI-0137 v4 (7 October 2026) explains the amended shortage and discontinuation reporting duties in SOR/2026-96, which start on 17 June 2027, the first anniversary of the regulation's publication.

What to do. If you sell device categories that are subject to reporting in Canada, update your shortage-reporting procedure before June 2027.

All devicesSupply & shortagesPost-market & vigilance
Sources (1) · verified against the instrument 19 Oct 2026
Australia
In force
Deadline: 1 Jul 2027

Australia: UDI labeling and database entry phase in from 1 July 2026

Regulations in force from 25 March 2025 require a UDI and an entry in the Australian UDI Database within 30 days of first supply on or after a device's start day. The first start day was 1 July 2026, for Class III and IIb devices not covered by an EU Directive certificate on 30 June 2026 (stock made and labeled before then has until 1 July 2029). Class IIa follows on 1 July 2027, and Class 4 IVDs and sterile Class I on 1 July 2028; devices with a Directive certificate in force get later dates.

What to do. Work out the start day for each ARTG entry and have the UDI data ready before it.

All devicesIVDLabelingPost-market & vigilance
Sources (1) · verified against the instrument 20 Oct 2026
Malaysia
In force
Deadline: 1 Oct 2027

Malaysia: product classification letters now expire after five years

From 1 October 2026 new MDA product classification letters are valid for five years. Two-year letters are extended to three. Letters more than five years old must be renewed by 1 October 2027, and only if nothing has changed; otherwise a new application is needed.

What to do. List your MDA classification letters by issue date and renew any older than five years before 1 October 2027.

All devicesClassification
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Chile
Final — not yet in force
Starts: 19 Mar 2028

Chile: Decree 25 makes registration mandatory for 39 device and IVD categories

Exempt Decree 25 (signed 6 March, published 19 March 2026) brings 39 listed device, IVD and software categories under ISP conformity verification, which takes the form of a sanitary registration assessed against the ISO 16142 essential principles. The obligation starts 24 months after publication for items 6 to 18 (mostly Class IV implants, plus insulin pumps and blood bags) and 36 months for the rest: by our count 19 March 2028 and 19 March 2029. Voluntary early registration opens once ISP issues its technical instruction, due within 12 months of publication. After registration, a significant change needs a new registration.

What to do. Check whether your products are on the list, and plan registration so it is granted before your category's deadline.

ImplantableActive (powered)Non-activeIVDSoftware & AIRegistration routeClassification
Sources (1) · verified against the instrument 20 Oct 2026
European Union
Final — not yet in force
Starts: 2 Aug 2028

European Union: AI Act high-risk obligations for AI medical devices move to 2 August 2028

Regulation (EU) 2026/1744 (8 July 2026) moves the AI Act's high-risk obligations to 2 August 2028 for AI systems that are high-risk because they sit in a product under Annex I, which includes medical devices and IVDs. Systems listed in Annex III move to 2 December 2027.

What to do. Certify under the MDR or IVDR now, and run an AI Act gap analysis during 2027.

Software & AIIVDSoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Australia
In force
In force: 1 Nov 2026

Australia: the exemption for clinical decision support software narrows on 1 November 2026

From 1 November 2026 decision support software stays exempt from ARTG inclusion only if it does not analyze an image or signal from another device, does not make the diagnosis or treatment decision itself, and shows the clinician the guidelines, calculations or logic behind each recommendation. The change also applies to software made before 1 November and used after it.

What to do. Before 1 November, test each exempt product against the new conditions, especially showing its logic. A product that fails needs an ARTG inclusion plan or different claims.

Software & AISoftware & AI rulesRegistration route
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
China
In force
In force: 1 Nov 2026

China: the revised device GMP applies from 1 November 2026

NMPA Announcement 2025 No. 107 (4 November 2025) issues a revised device GMP of 132 articles, replacing the 2014 version on 1 November 2026. It applies to registrants, filers and contract manufacturers, and brings outsourced design, contract manufacturing, outsourced processing and outsourced testing inside the quality system. Where manufacturing is contracted out, the contract manufacturer does production release and the registrant does release to market.

What to do. Check that quality agreements with contract manufacturers and test labs cover the controls the new GMP expects before 1 November.

All devicesQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
Egypt
Comment period closed
Comments closed: 1 Nov 2026

Egypt: EDA consults on the fourth edition of its guide to changing a notified imported-device registration

EDA's Central Administration for Medical Devices opened a 10-working-day stakeholder survey on Monday 19 October 2026 on the fourth edition of its guide to amending the data in a registration notification for an imported device holding international quality certificates. Comments go on EDA's feedback form to md.variation@edaegypt.gov.eg. By our count, on Egypt's Sunday-to-Thursday working week, the window closes on 1 November 2026. We have not compared the draft with the third edition.

What to do. If you plan design, labeling, site or software changes to an Egyptian registration, have your local holder review the draft and comment by 1 November.

All devicesSoftware & AIPost-market & vigilance
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 1 Nov 2026

China: GMP inspection guidance for the revised device GMP, from 1 November 2026

NMPA (Guoyaojianxieguan [2026] No. 14, 14 September 2026) issued the inspection guidance that goes with the revised device GMP and replaces the 2015 guidance from 1 November 2026. Until then, license inspections use the current GMP but also assess readiness for the new one; applications not yet inspected by 1 November are inspected under the new GMP. Provinces will plan inspections to cover every company in phases. From 1 November, sterile, implantable, IVD, custom denture and standalone software makers must meet the new GMP and the current appendices.

What to do. If you or your contract manufacturer make devices in China, run a gap check against the new inspection guidance before 1 November.

All devicesSoftware & AIImplantableIVDQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 30 Oct 2026

United States: a Class II device type for skin-lesion software used by non-specialist physicians is now in the regulations

A final order adds 21 CFR 878.1830, Class II with special controls, for prescription software that analyses the optical or other physical properties of a skin lesion and returns a classification, used by physicians not trained in diagnosing skin cancer as an adjunctive second read after they have found a suspicious lesion; it is not for standalone diagnosis. The special controls require clinical data showing that device-aided physicians are more accurate than unaided ones, at least 90% sensitivity for lesions with high metastatic potential (or a clinical justification for less), testing across skin phototypes with subgroup analysis, postmarket surveillance unless FDA decides it is not needed, and labeling that reports subgroup performance and describes the training population. The order codifies FDA's De Novo grant of 12 January 2024 (DEN230008), so the classification has applied since then; the order took effect on 30 October 2026. New devices of this type go through 510(k).

What to do. If you develop skin-lesion assessment software, plan your clinical study against these special controls, including the 90% sensitivity floor and phototype subgroups, and expect a 510(k) rather than a De Novo.

Software & AIActive (powered)Software & AI rulesClassification
Sources (1) · verified against the instrument 1 Nov 2026
United States
In force
In force: 30 Oct 2026

United States: a Class II device type for CT software that flags fibrotic lung disease for referral is now in the regulations

A final order adds 21 CFR 892.2085, Class II with special controls, for prescription software that analyses CT images to suggest fibrotic lung disease or a finding suggestive of it, with the output used as adjunctive information in a referral pathway. The special controls require clinical validation against a justified reference standard and an appropriate clinical control, such as clinicians doing the same task; pre-specified accuracy measures; enough cases in each relevant subgroup and image-acquisition setting to give confidence intervals; postmarket surveillance unless FDA decides it is not needed; a technical description of the algorithms; and labeling on compatible scanners and protocols, subgroup performance and limitations. The order codifies FDA's De Novo grant of 12 January 2024 (DEN220040), so the classification has applied since then; the order took effect on 30 October 2026. New devices of this type go through 510(k).

What to do. If you develop CT-based lung-disease software, use these special controls as your validation plan and expect a 510(k) rather than a De Novo.

Software & AISoftware & AI rulesClassification
Sources (1) · verified against the instrument 1 Nov 2026
European Union
In force
Published: 30 Oct 2026

European Union: uploading safety and performance summaries to EUDAMED moves to December 2026, recommended by 27 March 2027

MDCG 2026-4 rev.1 (October 2026) moves the planned date for manufacturers to start uploading the summary of safety and clinical performance (SSCP; implantable and Class III devices) and the summary of safety and performance (SSP; Class C and D IVDs) to EUDAMED. That function is now planned for December 2026, not October. Until it is live, notified bodies upload the master summary with each new or updated certificate. The manufacturer then uploads the master and its translations, and the notified body marks which version it validated. For devices on the market before 28 May 2026, the recommended latest upload date moves from 27 February to 27 March 2027. Notified bodies have until 27 May 2027 to register existing certificates. The paper is guidance and is not legally binding.

What to do. If you hold a certificate for an implantable, Class III or Class C/D IVD device, agree with your notified body who uploads which summary, and plan your uploads for between December 2026 and 27 March 2027.

ImplantableActive (powered)Non-activeIVDAdministrativePost-market & vigilance
Sources (1) · verified against the instrument 1 Nov 2026
India
Comment period closed
Comments closed: 24 Oct 2026

India: draft CDSCO guidance for IVD manufacturing license applications

CDSCO published draft guidance for manufacturers applying for IVD manufacturing licenses on its online system and NSWS, section by section against the checklist. Comments are due within 15 days of publication on 9 October 2026, so by 24 October 2026 by our count. It is an awareness document, not a rule change.

What to do. If you make IVDs in India, check your next license application against the draft and send comments by 24 October.

IVDRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
Deadline passed: 21 Oct 2026

European Union: the last 2026 window to request a joint scientific consultation closes 21 October

A joint scientific consultation lets a developer shape the comparator and endpoints a later joint assessment will ask about. It must be requested while the pivotal study is still a plan. The 2026 work program plans two to five device consultations; the last request period runs 23 September to 21 October 2026.

What to do. If your device is likely to be selected and the study is not yet running, request a consultation before 21 October, or watch for the 2027 windows.

ImplantableActive (powered)IVDHTA & reimbursementClinical evidence & trials
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
European Union
Draft
Published: 20 Oct 2026

European Union: the Commission's proposal to simplify the MDR and IVDR is still in Parliament committee

COM(2025) 1023 (16 December 2025) would remove the 5-year limit on certificates in favour of risk-based periodic reviews, allow surveillance audits every two years where there are no safety issues and make unannounced audits for-cause, cut notified-body review of Class IIa/IIb and B/C devices to representative devices, take sterile Class A IVDs out of notified-body review, limit the summary of safety and (clinical) performance to devices whose technical documentation the notified body assesses, give 30 days instead of 15 for some serious-incident reports, and add priority review for breakthrough and orphan devices and notified-body fee cuts for micro and small makers. None of this is law. The Parliament committee (SANT) has a draft report (30 June 2026) but has not voted; the indicative plenary date is 14 December 2026.

What to do. Keep planning to the MDR and IVDR as they stand; budget certification and surveillance on today's rules, not the proposal.

All devicesRegistration routePost-market & vigilanceFees
Sources (2) · verified against the instrument 20 Oct 2026
European Union
In force
Published: 20 Oct 2026

European Union: guidance on breakthrough devices, with designation by the expert panels

MDCG 2025-9 (December 2025) sets the criteria for a breakthrough device: a high degree of novelty and a significant positive clinical impact for a life-threatening or irreversibly debilitating condition, either better than the alternatives or meeting an unmet need. The manufacturer asks the expert panels for an opinion on breakthrough status at any stage of development; the panels aim to answer within 60 days. A designated device can get early advice from the expert panels and priority and structured dialogue with its notified body; the guidance is not binding, and the Commission said a pilot was expected in Q2 2026.

What to do. If your device is genuinely novel and addresses a serious condition, prepare the breakthrough-status application early; it is the closest EU equivalent to an early-engagement route.

All devicesRegistration routeClinical evidence & trials
Sources (2) · verified against the instrument 20 Oct 2026
United States
Draft
Deadline passed: 16 Oct 2026

United States: FDA proposes moving breast tomosynthesis and cystoscopic bladder-cancer detection systems to Class II

Two proposed orders would move Class III device types into Class II with special controls, subject to 510(k): digital breast tomosynthesis systems (product code OTE; proposed 10 August 2026, comments closed 9 October 2026) and diagnostic endoscopic light source systems, to be renamed cystoscopic systems intended as an aid for detection of bladder cancer (product code OAY; proposed 17 August 2026, comments closed 16 October 2026). Neither order is final, so PMA still applies until a final order takes effect.

What to do. If you are developing either device type, wait for the final order before choosing between a PMA and a 510(k).

Active (powered)ClassificationRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
United States
Draft
Deadline passed: 16 Oct 2026

United States: FDA proposes classifying certain accessories on their own in Class I, exempt from 510(k)

A notification of 17 August 2026 lists accessories, each already cleared or approved as part of another device, that FDA proposes to classify in Class I separately from the parent device and exempt from 510(k). The list covers cardiovascular, gastroenterology-urology and general surgery accessories, such as the tubing that connects a blood-pressure cuff to its monitor and mounting brackets in an ECMO circuit. Comments closed on 16 October 2026; nothing changes until FDA publishes the final list.

What to do. If you make an accessory of a listed type, compare your product with the proposed identification before planning a separate 510(k).

Active (powered)Non-activeClassificationRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
China
Comment period closed
Comments closed: 12 Oct 2026

China: CMDE consulted on a 2026 revision of its AI device review guideline

CMDE published a draft 2026 revision of its Guideline for Registration Review of AI Medical Devices on 14 September 2026, with comments due by 12 October 2026. Earlier, on 10 June 2026, it consulted on draft guidelines for clinical evaluation of AI-assisted diagnosis devices and for clinical trials of diabetic retinopathy diagnosis software, with comments due by 10 July 2026. Both consultations have closed.

What to do. If you plan to register AI software in China, read the drafts now and expect the final versions to apply to your file.

Software & AISoftware & AI rulesClinical evidence & trials
Sources (2) · verified against the instrument 20 Oct 2026
Kenya
Not a device change
Published: 9 Oct 2026

Kenya: the new GMP reliance guideline covers medicines, not devices

The Pharmacy and Poisons Board's guideline on relying on other authorities' GMP decisions (posted 9 October 2026) applies to manufacturing sites for finished pharmaceutical products, active ingredients and contract research organizations. Kenya's device reliance routes are separate and unchanged.

What to do. No change for device makers; plan on Kenya's January 2025 device reliance routes.

All devicesReliance & recognitionQMS & GMP
Sources (1) · verified against the instrument 19 Oct 2026
Argentina
In force
In force: 7 Oct 2026

Argentina: GMP certificates for foreign device plants on the strength of an accredited ISO 13485 certificate

ANMAT Disposición 6403/2026 (in force 7 October) sets out how a GMP certificate is issued for a foreign device or IVD plant outside the Mercosur inspection regime: the importer files a current ISO 13485 certificate from a body accredited by an ILAC or IAF member, and ANMAT has 40 business days to evaluate, ask for more, or verify virtually or on site based on risk. One certificate per application.

What to do. Check your ISO 13485 certificate is from an accredited body and covers every plant and category you will file; plants on separate certificates need separate applications.

All devicesIVDQMS & GMPReliance & recognition
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United States
In force
In force: 6 Oct 2026

United States: the 510(k) exemption for workplace drug tests now covers federal testing programs

A final order covers 14 drug-of-abuse test types (21 CFR 862.3100–862.3910). Tests labeled solely for employment and insurance testing are now 510(k)-exempt even when used in federal programs such as SAMHSA, DOT or the military, within the limits of 21 CFR 862.9. Fentanyl tests fall under the opiate regulation (product code DJG moves to PVH). Clinical and point-of-care drug tests are not affected.

What to do. If you sell a drug screen for employment or insurance testing, check that your labeling carries the required statement; a new product within those limits no longer needs a 510(k).

IVDRegistration route
Sources (1) · verified against the instrument 19 Oct 2026
United Kingdom
Announced
Published: 6 Oct 2026

Great Britain: government accepts all 44 recommendations on regulating AI in healthcare

The government response (6 October 2026) commits to draft guidance on predetermined change control plans by December 2026 and a consultation on how software and AI are qualified and classified by spring 2027, followed by secondary legislation. No law has changed yet.

What to do. Diary December 2026 for the draft change-control guidance and plan to comment on it.

Software & AISoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
ThailandMalaysia
In force
In force: 6 Oct 2026

Thailand puts Malaysia's MDA on its legal list of recognized foreign agencies

A Thai FDA notification signed 6 October 2026 adds Malaysia's Medical Device Authority as item 8 of the list of foreign agencies whose device approvals Thailand accepts. It covers devices approved by MDA under the MDA–Thai FDA reliance program, not approvals granted without MDA's safety and performance evaluation. Intended use, labeling, instructions and packaging must be identical to the Malaysian approval. Unlike the US, EU, Canadian, Australian and Japanese approvals on the same list, which must have been held for at least a year, HSA and MDA approvals carry no holding period.

What to do. If Malaysia is filed or planned, keep the Malaysian labeling and instructions identical to what you will file in Thailand, and ask your Thai license holder to cite the notification.

All devicesReliance & recognition
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United Kingdom
In force
In force: 6 Oct 2026

United Kingdom: applications to the MHRA's AI Airlock sandbox are open; apply by 31 October for the current wave

Phase 3 of the MHRA's regulatory sandbox for AI-enabled medical devices opened on 6 October 2026. Organizations of any size may apply, prototypes included, with priority for proposals on post-market surveillance and lifecycle oversight. There is no fee, but participants fund their own studies and testing, typically 6 to 12 months. The window stays open all year: applications made before 31 October join the current review wave, later ones the next, with shortlisting in spring 2027. The phase is funded to April 2029.

What to do. If your AI device raises a regulatory question you would rather test with the MHRA than guess at, apply by 31 October.

Software & AISoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Japan
In force
In force: 5 Oct 2026

Japan: PMDA sets out when a test becomes a companion diagnostic for a cancer drug, and when to consult

A PMDA 'Early Consideration' dated 5 October 2026 (posted 19 October), issued jointly by its new-drug, software-as-a-medical-device and IVD review offices, covers tests developed alongside anti-cancer drugs. It sets the factors that decide whether a test is a companion diagnostic, and asks drug and test developers to consult PMDA as early as possible, at the latest at the consultation on the pivotal trial. A test that already measures the biomarker may still need a companion-diagnostic approval or partial change if its intended use does not name the drug. If the marketed test differs from the trial assay, the developer must show analytical equivalence. The test should normally be covered by national health insurance by the date the drug is price-listed. It is non-binding reference guidance, not a new rule; the 2013 principle of filing the test and the drug together is unchanged.

What to do. If you are developing a companion test with a drug sponsor in Japan, agree a PMDA consultation before the pivotal trial and plan your filing from the drug's expected price-listing date, allowing for review and insurance coverage.

IVDSoftware & AIRegistration routeClinical evidence & trialsHTA & reimbursement
Sources (2) · verified against the instrument 1 Nov 2026
European Union
In force
In force: 2 Oct 2026

European Union: the first medical devices picked for joint clinical assessment

Implementing Decision C(2026) 7113 (2 October 2026) picks two transcatheter mitral valve systems, SAPIEN M3 (Edwards) and HighLife (HighLife SAS), for the first device assessments under the HTA Regulation. Only devices that receive an MDR expert-panel opinion can be selected: Class III implants, Class IIb devices that administer or remove medicines, and Class D IVDs. A joint assessment sets no price; member states must give it due consideration. The dossier is due within 100 days.

What to do. If your device will go through the MDR expert-panel consultation, plan the joint-assessment dossier alongside the clinical evaluation, not after it.

ImplantableActive (powered)IVDHTA & reimbursementClinical evidence & trials
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
United States
In force
In force: 1 Oct 2026

United States: a Breakthrough designation no longer qualifies a device for Medicare's add-on payments by itself

The FY 2027 hospital payment final rule repeals the alternative pathway that let a Breakthrough-designated device qualify for the inpatient new-technology add-on payment and the outpatient device pass-through payment without showing substantial clinical improvement. From FY 2028 add-on payment applications, and for pass-through applications after 30 September 2026, every device must meet all the usual criteria; an add-on payment also needs FDA marketing authorization by 1 May before the fiscal year. A device designated Breakthrough by 30 September 2026 keeps the old route for a limited time: through FY 2029 for the add-on payment if it is authorized by 1 May 2028, and through calendar year 2029 for pass-through once authorized.

What to do. If your designation came after 30 September 2026, budget on proving substantial clinical improvement for Medicare payment; if it came before, check whether you can be authorized by 1 May 2028.

All devicesHTA & reimbursement
Sources (1) · verified against the instrument 30 Oct 2026
Taiwan
In force
In force: 1 Oct 2026

Taiwan: device trials move onto one online platform, with new rules on recruitment

From 1 October 2026 sponsors must register device-trial data on mdctp.fda.gov.tw within 30 days of approval or an approved amendment, and update it every June and December. From 5 October the revised application instructions route every filing (new applications, amendments, progress and final reports) through the same platform. Since 21 September, TFDA's recruitment notes say adverts need ethics-committee approval and may not name the investigational device or the company, claim safety or superiority, or promise free product. Approval rules are unchanged.

What to do. Check every running Taiwanese trial is on the platform before the December update, and have recruitment copy re-checked before it goes to the ethics committee.

All devicesClinical evidence & trials
Sources (3) · verified against the instrument 19 Oct 2026
Read the analysis →
Chile
In force
In force: 1 Oct 2026

Chile: ISP publishes the scope table for mandatory device registration under Decree 25

ISP's first information note (1 October 2026) lists the 39 categories Decree 25/2026 brings under mandatory registration, with risk class, what is and is not covered, and the deadline for each: 24 months for categories 6–18 (mostly Class IV implants) and 36 months for the rest. Two software categories are included. Voluntary early registration opens only when ISP's technical instruction is published.

What to do. Check your portfolio against ISP's include and exclude columns, and watch for the technical instruction.

ImplantableActive (powered)Non-activeIVDSoftware & AIRegistration routeClassification
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
China
In force
In force: 1 Oct 2026

China: the revised National Defense Mobilization Law names the call-up of medical equipment

China's National Defense Mobilization Law, revised on 28 August 2026 and in force on 1 October 2026, says that once the state decides to implement national defense mobilization it mobilizes medical institutions and staff and calls up drugs, equipment (器材) and facilities for wartime medical care (Article 54). Organizations in the pharmaceutical and health sector must take on national defense service duties and train for them in peacetime (Article 60). In a mobilization area, the State Council and the Central Military Commission may put the pharmaceutical and health industry under control (Articles 73 and 74). The law sets out no device registration route.

What to do. If you make devices in China or hold stock there, a mobilization order can call up that stock and put your sector under state control. There is nothing to apply for in peacetime.

All devicesSupply & shortages
Sources (1) · verified against the instrument 4 Nov 2026
Singapore
In force
In force: 1 Oct 2026

Singapore: new declaration and ISO 13485 certificate rules for every registration route

From GN-15 Revision 14 (14 September 2026) every Class B, C and D application, on every route, needs a declaration on device labeling, adverse events and field safety corrective actions (Annex 4). Revision 15 (1 October 2026) adds a premarket submission checklist and requires ISO 13485 certificates to come from a certification body accredited by a Global ACI-recognized accreditation body, or from an EU MDR/IVDR notified body.

What to do. Check that your ISO 13485 certificate's issuer meets the new rule before you file, and add the Annex 4 declaration to every new application.

All devicesIVDRegistration routeQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
Taiwan
In force
In force: 1 Oct 2026

Taiwan: registration filings move online, with no paper copies of approved labels

From 1 October 2026, as a trial, filings through TFDA's electronic submission system for Class 1, 2 and 3 registration, license changes and renewals are made as color scans. The paper originals are kept by the license holder rather than posted. TFDA no longer issues paper copies of approved labels, IFUs or packaging for Class 2 and 3 approvals; the approved version is published in its license database. Fees for electronic filings are paid only through that system.

What to do. Give your license holder clean color scans, and keep your own controlled copy of each approved label.

All devicesAdministrativeLabeling
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 1 Oct 2026

United States: FY2027 device user fees apply from 1 October 2026

FDA's fee notice for fiscal year 2027 sets the 510(k) fee at $28,653 ($7,163 for a qualifying small business), De Novo at $191,020 ($47,755) and an original PMA at $636,732 ($159,183). The annual establishment registration fee is $13,785, with no small-business reduction. The rates apply from 1 October 2026 to 30 September 2027. A business with gross receipts of $100 million or less, affiliates included, can qualify for the small-business rates, and one at $30 million or less can have the fee for its first premarket application waived.

What to do. Get small-business status confirmed before you file, and budget the establishment fee even if your US sales are small.

All devicesFees
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
Applied; rule pending
Applied from: 30 Sep 2026

South Korea: Class 2 technical review and certification in one application

Since 30 September 2026 an applicant can file the technical-document review and the Class 2 certification together, with a 25-day processing period. Before, the review came first from one of eight designated review bodies, then a separate certification application. The old two-step route stays open. MFDS applied the change administratively; the rule amendment is in consultation until 26 October and takes effect on 10 December 2026.

What to do. Ask your Korean license holder which route your next Class 2 filing will take. Treat 25 days as the authority's processing period, not your time to first sale.

All devicesRegistration route
Sources (1) · verified against the instrument 14 Oct 2026
Vietnam
In force
In force: 30 Sep 2026

Vietnam: more appraisal bodies for registration dossiers, paid directly by the applicant

Decision 3046/QĐ-BYT (30 September 2026) replaces the January 2024 list of bodies that appraise device dossiers on the standard registration route (used by devices without a reference-country approval). IVD appraisers widen from one to three; applicants now pay the appraising body directly at its own published price. The 10-working-day fast track for devices with a reference-country approval is unchanged.

What to do. If you file in Vietnam without a reference approval, ask your registration holder which body will appraise the dossier and at what price, and budget it separately from the state fee.

All devicesIVDRegistration routeFees
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United Kingdom
Not a device change
Published: 30 Sep 2026

United Kingdom: the 14-day Phase 1 trial assessment excludes trials involving devices

The MHRA's stepwise program cutting first review of qualifying Phase 1 medicines trials to 14 days by 28 December 2026 excludes trials that involve a medical device, an IVD or a companion diagnostic.

What to do. Plan device and combination studies on the standard MHRA routes.

All devicesClinical evidence & trials
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
SingaporeSaudi ArabiaMalaysia
Not a device change
Published: 17 Sep 2026

Singapore: HSA's new partnerships do not create a device route

HSA's 17 September 2026 release describes MoUs with the Saudi FDA and the African Medicines Agency and a Malaysian pilot that references HSA's assessments of medicines. None creates a submission route, fee or procedure for a medical device; devices appear only through international harmonisation work.

What to do. Do not plan a Saudi, Malaysian or African device filing around an HSA approval on the strength of this release.

All devicesReliance & recognition
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United States
Not a device change
Published: 17 Sep 2026

United States: radiology CAD and triage software still needs a 510(k)

A final order published on 17 September 2026 carries the title 'Exemption From Premarket Notification', but it records a denial. A petition had asked FDA to exempt four radiology software types (21 CFR 892.2060, 892.2070, 892.2080 and 892.2090: computer-aided detection, diagnosis, and triage and notification) from 510(k) for companies that already held a clearance under the same regulations. FDA denied the petition on 1 April 2026 and the order confirms that a 510(k) is still required.

What to do. Plan a 510(k) for each new radiology CAD or triage product, even if you already hold a clearance of the same type.

Software & AISoftware & AI rulesRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
Hong Kong
Announced
Published: 16 Sep 2026

Hong Kong: a bill to regulate medical devices promised 'within the year'

The 2026 Policy Address (16 September) says the government will set up the Centre for Medical Products Regulation and submit a legislative proposal on regulating medical devices within the year. The 2025 Policy Address made the same promise. No bill has been published, and the voluntary listing system remains.

What to do. No action yet. Keep listings current and watch for the bill.

All devicesRegistration route
Sources (1) · verified against the instrument 19 Oct 2026
Russia
In force
Published: 16 Sep 2026

Russia: new administrative rules for national device registration, with a 10-day clock for AI software changes

Roszdravnadzor Order 750 (published 16 September 2026) replaces the 2019 rules for national registration. Maximum service times run from 31 working days without human trials to 50 with them, and 10 working days for changes to the dossier of AI software. The result is an entry in the state register; no certificate is issued.

What to do. For Russian national files, plan to the new maximum times. They are statutory limits, not observed times.

All devicesSoftware & AIRegistration routeSoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
United States
In force
In force: 16 Sep 2026

United States: in situ hybridization tests tied to an approved cancer therapy move from Class III to Class II

A final order of 17 August 2026, effective 16 September 2026, reclassifies ISH test systems indicated for use with an approved oncology therapeutic (product codes NYQ, MVD, OWE and PNK) from Class III into Class II with special controls, so a new test needs a 510(k) rather than a PMA. Tests already approved by PMA can stay on the market under that approval; a significant change to one after the effective date goes through a 510(k).

What to do. If you are developing an ISH companion test, plan a 510(k) against the new special controls rather than a PMA.

IVDClassificationRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 11 Sep 2026

United States: a new Class II device type for cardiovascular machine-learning notification software

A final order adds 21 CFR 870.2380, with special controls, for machine-learning software that suggests the likelihood of a single cardiovascular condition so the patient can be referred. It does not cover arrhythmia detection or diagnostic-quality output.

What to do. If you build referral software of this kind, use the special controls as your evidence plan, including for filings outside the US.

Software & AISoftware & AI rulesClassification
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Vietnam
In force
In force: 11 Sep 2026

Vietnam: an apostille replaces consular legalization for documents from Convention countries

Decree 293/2026/ND-CP (23 July 2026, in force 11 September 2026) implements the Apostille Convention. A public document from a Convention member now needs an apostille instead of consular legalization, and a certified Vietnamese translation. The decree is general, not device-specific, and excludes administrative documents directly related to commercial or customs operations.

What to do. Ask your Vietnamese registration holder whether the device desk accepts apostilled free-sale certificates and authorization letters before you skip legalization.

All devicesImport & licensingAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
In force: 9 Sep 2026

European Union: IVD classification guidance clarifies that standalone quality-control materials stay Class B

MDCG 2020-16 rev.5 (September 2026) changes only Rule 7: it clarifies the rationale and revises the examples. A manufacturer of standalone quality-control material may state the presence or concentration range of the analyte; those indicated values are not 'assigned values', so unless another rule applies the control is Class B. Controls with values assigned by the manufacturer, including assay-kit validity controls, are classified under implementing rule 1.6.

What to do. If you make third-party QC material, check that your instructions for use limit its purpose to monitoring the laboratory's examination procedure and that your stated ranges read as indicative, not assigned.

IVDClassification
Sources (1) · verified against the instrument 20 Oct 2026
Saudi Arabia
In force
In force: 9 Sep 2026

Saudi Arabia: a reliance route for marketing authorization on an Australian, Canadian, EU, Japanese, UK or US approval

SFDA guidance MDS-G30 (version 1.0, 9 September 2026) lets an applicant for a Saudi marketing authorization (MDMA) cite an approval from Australia, Canada, the EU/EEA, Japan, the UK or the US for an identical device. It brings reduced documentation and a 35–60 working-day review in every class. Approvals granted 'primarily by demonstrating substantial equivalence to a predicate device' and self-declared approvals are excluded; our reading is that a US 510(k) or a self-certified EU Class I does not qualify on its own, while a PMA or De Novo does. SaMD and AI-enabled devices may be excluded at SFDA's discretion, and SFDA accepts MDSAP certificates and audit reports as quality-system evidence.

What to do. If you hold a PMA, De Novo, notified-body CE, UK, Canadian, Australian or Japanese approval for the identical device, file through the reliance route with the Reliance Form; if your only approval is a 510(k), plan the standard route or put the question to SFDA in writing first.

All devicesIVDReliance & recognitionQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
Australia
In force
In force: 8 Sep 2026

Australia: saline flush syringes and locking solutions are now Class IIa

A new classification rule makes non-invasive devices that contain only saline and flush or keep open another device Class IIa (Class III with an ancillary medicine), for new applications from 8 September 2026. Existing entries have five years to transition.

What to do. Make new applications under the new rule; plan transition of existing entries.

Non-activeClassification
Sources (1) · verified against the instrument 19 Oct 2026
Hong Kong
In force
In force: 8 Sep 2026

Hong Kong: e-signed certificates accepted for device listing, and longer supply-record retention

MDACS guidance GN-01 (revised 1 and 8 September 2026) accepts an electronic certificate when its signature can be verified on the issuer's official website, lets the Medical Device Division ask for a certified copy or check a document with the issuer, and requires the Local Responsible Person to keep supply records for the device's projected service life or seven years, whichever is longer.

What to do. Submit e-signed CE or FDA certificates as they are where the issuer offers online verification, and check your record retention.

All devicesRegistration routePost-market & vigilance
Sources (1) · verified against the instrument 19 Oct 2026
Australia
In force
In force: 8 Sep 2026

Australia: devices for Defence no longer need an ARTG entry

Since 8 September 2026, devices manufactured in Australia for the Defence Department, imported or exported for it, or supplied for it or by a Defence medical practitioner, are exempt from inclusion on the ARTG. The conditions: a Defence medical practitioner directs use, a Defence clinical governance committee considers the device appropriate before it is used, Defence keeps custody and records, and it gives the records to TGA on request. The change is item 2.20 of Schedule 4 Part 2 of the Medical Devices Regulations. Before it, the only Defence-related exemption covered visiting foreign forces.

What to do. If you make a trauma or field-care device, the decision in Australia sits with Defence's clinical governance committee, not TGA. Approach the Defence medical service with your quality and bench evidence.

All devicesRegistration routeImport & licensing
Sources (1) · verified against the instrument 2 Nov 2026
Read the analysis →
Indonesia
In force
In force: 7 Sep 2026

Indonesia: imported AI for diagnosis or screening needs local clinical validation

Ministerial Decree KMK 951/2026 (in force 7 September 2026) sets out marketing authorization for software devices. Imported moderate- or high-risk AI used for diagnosis, screening or clinical decisions needs local clinical validation, which can run in parallel with the application, with results due within a year of the grant. A regulatory sandbox is available.

What to do. Budget a validation study at an Indonesian hospital, university or accredited laboratory for any imported diagnostic or triage AI. The one-year clock starts at the grant.

Software & AISoftware & AI rulesClinical evidence & trials
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Colombia
In force
In force: 7 Sep 2026

Colombia: a new supply-alert system, with device stock reporting limited to a priority list still to come

Resolution 1763 of 2026 (in effect from its publication on 7 September) creates SISCAATS. For devices, the monthly availability report covers only devices the Ministry puts on a priority list, which it has not yet published. The Ministry has six months from publication to switch availability reporting on, and each report becomes mandatory two months after it is. Incident reports (events that disrupt supply) start sooner.

What to do. Agree now who in your Colombian distribution files SISCAATS reports, and watch for the device priority list.

All devicesSupply & shortages
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United States
Not a device change
Published: 3 Sep 2026

United States: the 2026 military emergency declaration covers pain drugs, not devices

On 15 July 2026 the Secretary of War determined a military emergency involving acute pain in casualties, and on 31 August 2026 HHS declared that emergency use authorization of drugs for moderate to severe acute pain is justified. The declaration names drugs only. The 2018 declaration on the same military ground covers freeze-dried plasma. Section 564 can reach devices, but no declaration on a military ground covers one.

What to do. No device route opens from this notice. A trauma device would need its own determination and declaration, which only the Department can start.

All devicesRegistration route
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Canada
In force
In force: 2 Sep 2026

Canada: shortage imports of foreign-authorized devices now need 3 business days' notice

Health Canada's updated forms (2 September 2026) cut the notice before a shipment arrives from 5 to 3 business days and ask for more evidence. Guide GUI-0147 v2 (7 October) revises the criteria for adding a device to the exceptional importation list. Both implement SOR/2026-96.

What to do. If you supply Canada through the exceptional importation list, brief your importer on the shorter notice and the new evidence fields.

All devicesSupply & shortagesImport & licensing
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
MexicoBrazil
Not a device change
Published: 2 Sep 2026

Mexico: the September agreement recognizing Brazil's ANVISA covers medicines, not devices

The 2 September 2026 Acuerdo recognizing ANVISA for an abbreviated route applies to medicine registrations only; the word 'dispositivo' does not appear. For devices, Mexico's July 2025 abbreviated route already recognizes IMDRF Management Committee members, Brazil included.

What to do. Use the 2025 abbreviated device route; settle the local registration holder first.

All devicesReliance & recognition
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
United Kingdom
Draft
Published: 1 Sep 2026

United Kingdom: Health Bill amendments would give the MHRA powers to build a device licensing regime

The government tabled three amendments to the Health Bill (announced 1 September 2026). They would widen the MHRA's information-sharing powers, let device and medicines legislation automatically pick up updated standards and guidelines, and amend the Medicines and Medical Devices Act 2021 to enable a future licensing regime under which devices placed on the Great Britain market through a domestic route could need an MHRA license instead of a third-party conformity assessment. Nothing changes immediately; any regime would need consultation and further legislation.

What to do. No action now; watch the Bill's progress and any consultation on device licensing.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
Argentina
In force
In force: 1 Sep 2026

Argentina: ANMAT caps the device import fee at ARS 5 million

Disposición 5461/2026 (dated 27 August, published 28 August 2026) sets a maximum fee of ARS 5,000,000 for medical devices on foreign-trade procedures (ARS 12,000,000 for medicines), keeping the existing scales and percentages. The new fee schedule applies to procedures started on or after 1 September 2026.

What to do. Re-run landed-cost estimates for high-value shipments; the cap matters most for capital equipment.

All devicesFeesImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 19 Aug 2026

India: an EU approval now counts towards waiving Indian trials for devices with no predicate, but not for new IVDs

G.S.R. 744(E) adds EU countries to the list of reference countries whose approval (with two years on the market) can waive the Indian clinical investigation for a device with no Indian predicate, decided case by case. New IVDs are approved under a different rule with no reference-country waiver, and need clinical performance data from India.

What to do. For a novel device with two years of EU marketing, ask CDSCO about the waiver. For a novel IVD, budget an Indian clinical performance evaluation.

All devicesIVDReliance & recognitionClinical evidence & trials
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
France
In force
In force: 19 Aug 2026

France: devices made to Defense order can now be distributed by any armed forces health service entity

France's Public Health Code lets ANSM authorize the Minister of Defense to use a device that lacks its MDR certificate, when no suitable device is available and the use meets specific national-defense needs (L.5211-3 IV; L.5221-3 IV for IVDs). The military programming law of 16 August 2026 (Article 24) widens who may distribute devices made to the ministry's order, from the armed forces health service's supply depots to "toute entité" of that service. The same article lets the service distribute crisis stocks with other state services' help in a chemical, biological, radiological or nuclear emergency.

What to do. The route belongs to the Ministry of Defense, not the manufacturer. If your device answers a defense need, the conversation is with the armed forces health service (SSA), which applies to ANSM.

All devicesIVDRegistration routeSupply & shortages
Sources (1) · verified against the instrument 2 Nov 2026
Read the analysis →
France
In force
In force: 19 Aug 2026

France: the Defense Ministry can now order any company to hold stocks for the forces' health equipment

Article L.1339-1 of the Defense Code lets the authority, after consulting the company, order a minimum stock of strategic materials, components, spare parts or semi-finished products, and the stock can cover up to 24 months of the forces' needs. The military programming law of 16 August 2026 (Article 10) widens it in two ways. It now covers equipment needed for the forces' logistical, digital, energy or health support, not only weapons. And it reaches any company, where before it reached only holders of an arms-trade authorization. Products held under the Public Health Code's strategic stock rules for medicines are excluded. Costs of building and keeping the stock are not compensated.

What to do. If you make or supply components for devices the French armed forces use, expect that a stock order can reach you, and that its cost is yours. It changes nothing about how your device is certified.

All devicesSupply & shortages
Sources (1) · verified against the instrument 4 Nov 2026
European Union
Not a device change
Published: 19 Aug 2026

European Union: the August 2026 joint-assessment eligibility checker and early-information guidance cover medicines, not devices

On 19 August 2026 the Commission updated its guidance on submitting early information for joint clinical assessment and launched an eligibility checker. Both apply to medicinal products, alongside EMA's pre-authorization forms. Devices are not self-declared into scope: the Commission selects them by implementing decision.

What to do. No action for device makers; watch for the Commission's device selections instead.

All devicesHTA & reimbursement
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 19 Aug 2026

India: the list of low-risk devices that need only online registration, and a new quality-system declaration for them

Class A devices that are neither sterile nor measuring need only online registration in India, not a license. In October 2025 CDSCO published a list of 1,069 device types in this group. Since G.S.R. 744(E) took effect on 19 August 2026, manufacturers and importers registering them must self-certify compliance with a quality management system as well as with standards; a December 2025 draft (G.S.R. 883(E)) that would also put the registration number on the label is not final.

What to do. Check whether your low-risk device is on the list, and keep a quality-system file ready before you self-certify.

Non-activeClassificationQMS & GMP
Sources (3) · verified against the instrument 20 Oct 2026
United States
In force
In force: 11 Aug 2026

United States: Medicare's TCET coverage route is closed to new devices, and RAPID is proposed in its place

CMS stopped taking new candidates for the Transitional Coverage for Emerging Technologies (TCET) pathway when it published its RAPID coverage pathway notice on 11 August 2026. Under RAPID, a Breakthrough-designated device would get a proposed Medicare national coverage determination on the day of FDA marketing authorization, with the final determination about 60 days later for Class II and 90 days for Class III; CMS says the usual process takes 9 to 12 months. It is open to Class II Breakthrough devices in FDA's TAP program planning a De Novo request, and Class III Breakthrough devices planning a PMA, still at the IDE pre-submission stage, whose IDE study enrolls Medicare beneficiaries and measures outcomes FDA and CMS agree on in advance. IVDs will not be accepted. Comments closed on 13 October 2026; as of 30 October CMS had not published the final process.

What to do. If you hold or expect a Breakthrough designation and Medicare patients matter to you, settle the coverage outcomes with FDA and CMS at the IDE pre-submission, before the pivotal study is designed. TCET is not an option for a new device.

ImplantableActive (powered)Non-activeSoftware & AIHTA & reimbursementClinical evidence & trials
Sources (1) · verified against the instrument 30 Oct 2026
China
In force
In force: 8 Aug 2026

China: revised Greater Bay Area guide for hospitals importing devices used in Hong Kong and Macao

Guangdong MPA and the Guangdong Health Commission issued revised application guides (notice of 25 June 2026), in force from 8 August 2026 and replacing the 2024 guide. Under this scheme, designated hospitals in the nine mainland Greater Bay Area cities can import a device that is not registered by NMPA if it is clinically urgent, already bought and used by Hong Kong or Macao public hospitals, and clinically advanced, after Guangdong approval. The hospital applies; it is not a registration.

What to do. If your device is used in Hong Kong public hospitals but not registered in mainland China, a designated Bay Area hospital is the applicant to approach.

All devicesRegistration routeImport & licensing
Sources (2) · verified against the instrument 20 Oct 2026
India
In force
In force: 21 Jul 2026

India: CDSCO's final guidance on medical device software, including IVD software

The guidance classifies standalone software, including IVD software, and says it reflects current practice rather than a new control. Software embedded in an analyser is part of the analyser; separately supplied software that drives an analyser is an IVD in its own right. A separate CDSCO FAQ says every new software version of an approved IVD needs a post-approval change.

What to do. Classify standalone software on the guidance grid and plan your release cadence around post-approval changes.

Software & AIIVDSoftware & AI rulesClassification
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Vietnam
In force
In force: 1 Jul 2026

Vietnam: a new state-of-emergency law lets the Prime Minister take measures no law yet provides for

Vietnam's Law on State of Emergency (No. 104/2025/QH15), passed on 3 December 2025, took effect on 1 July 2026 and replaced the 2000 ordinance. It covers emergencies over disasters, security and defense. Where it is truly necessary for life and health, the Prime Minister may, with the consent of the competent authority, apply measures that the law does not yet provide for, and may apply the law's measures before an emergency is declared (Article 12(2)(c)). Businesses must switch production on request to supply materials, essentials and equipment, and must comply with orders mobilizing their equipment (Article 34).

What to do. No device route opens in peacetime. In a declared emergency the Prime Minister's power is broad enough to set registration rules aside, so a local partner and a registration already in place matter more, not less.

All devicesSupply & shortages
Sources (1) · verified against the instrument 4 Nov 2026
South Korea
In force
In force: 1 Jul 2026

South Korea: GMP conformity assessment written into the Medical Devices Act

From 1 July 2026 the Act itself requires manufacturers and importers to pass an MFDS review of their manufacturing and quality system before licensing. MFDS can cancel a conformity certificate obtained by fraud and order corrections for other breaches. Existing certificates carry over for their remaining validity. Designations of technical-document review bodies and quality-review bodies now last four years and must be renewed; existing ones run four years from 1 July 2026. Provisions restricting sales to medical institutions with a special relationship to the seller take effect on 31 December 2027.

What to do. Check the validity dates on your KGMP certificate and on the review body you use, as both now have fixed terms.

All devicesQMS & GMP
Sources (2) · verified against the instrument 20 Oct 2026
Switzerland
Announced
Published: 29 Jun 2026

Switzerland: plans to accept FDA-cleared or approved devices, with ordinances due by Q3 2027

On 30 April 2025 the Federal Council set guidelines for letting FDA-authorized devices onto the Swiss market: private bodies would check conditions in a simplified conformity assessment that takes account of the FDA's work, including Swiss data-protection law, a quality management system and a post-market surveillance plan, with clinical evidence possibly required. In a declaration of 29 June 2026, Switzerland said it intends to amend the ordinances by the third quarter of 2027. No draft ordinance has been published, and today only devices with a Swiss or EU declaration of conformity can be placed on the market.

What to do. If you hold only an FDA authorization, keep Switzerland on your list but plan entry through CE marking until the ordinances are published.

All devicesReliance & recognitionRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
China
In force
In force: 29 Jun 2026

China: brain-computer interface devices defined and classed, with AI moving rehab devices to Class III

NMPA Notice 2026 No. 24 (29 June 2026) issues classification and naming guidelines for brain-computer interface devices. A BCI device must read central nervous system signals, decode them in real time to drive its intended use, work in a closed loop and serve a medical purpose; EEG recorders and open-loop deep brain stimulators are not BCI devices, and non-medical BCI products are not devices. Invasive or implanted BCI devices are Class III. Non-invasive ones are Class III, except stroke limb-rehabilitation devices that use no AI, which are Class II.

What to do. If you develop a BCI product, use the guideline to fix its class and name, and note that adding AI to a rehab device moves it to Class III.

Active (powered)ImplantableSoftware & AIClassificationSoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
Taiwan
Draft
Published: 29 Jun 2026

Taiwan: draft fee increases for Class 1 and Class 2 registration, listing and annual reporting

MOHW published a draft amendment of the device administrative fee standard. Class 2 registration would rise from NT$58,000 to NT$62,000 and Class 1 registration from NT$15,000 to NT$26,000. License renewal would rise from NT$8,000 to NT$10,000, device listing from NT$10,000 to NT$15,000, annual reporting from NT$2,000 to NT$3,000, and classification enquiries from NT$3,500 to NT$5,000. A new NT$10,000 fee would apply to safety-related clinical trial amendments, and the NT$250,000 fee for 'first in the world' devices would be renamed 'first in Taiwan'. Comments were due within 60 days of publication in the Executive Yuan Gazette.

What to do. Budget for the higher fees on Taiwan filings planned for 2027.

All devicesFees
Sources (1) · verified against the instrument 20 Oct 2026
India
Draft
Published: 23 Jun 2026

India: draft rules would shorten the deadlines for licensing Indian device plants

Draft G.S.R. 515(E) would cut the authorities' time limits for domestic manufacturing licenses. For Class B, the state authority would screen the file in 30 days and the notified body would audit within 30 days of assignment, instead of 90 days from application; for Class C and D, CDSCO's scrutiny would fall from 45 to 30 days, the site inspection from 60 to 55 days, and the decision after the inspection report from 45 to 20 days. Comments closed 30 days after the 24 June 2026 Gazette (by our count, about 24 July 2026), and no final rule has been published.

What to do. If you plan to manufacture in India, watch for the final rule but do not plan on the shorter clocks yet.

All devicesRegistration routeQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
Taiwan
In force
In force: 8 Jun 2026

Taiwan: ten good machine learning practice principles for AI devices

TFDA published ten good machine learning practice principles for devices that use machine learning, based on the IMDRF principles. They cover intended use, software engineering and cybersecurity, representative clinical datasets, and post-market performance monitoring. Where a model was trained on non-Taiwanese data, the maker should assess how well it applies to the Taiwanese population, including any difference in performance, and provide data on it. The principles are for reference in design, development and maintenance.

What to do. If your AI device was trained abroad, plan a Taiwanese performance check before you file.

Software & AISoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 1 Jun 2026

South Korea: a pre-submission meeting and parallel review for innovative devices

MFDS put an expedited approval and review process for new drugs, biosimilars and innovative medical devices into effect on 1 June 2026, as part of a plan with a 240-day approval target. Applicants get a checklist of the items most often sent back, can request a face-to-face meeting with reviewers before filing, and review teams work on the file in parallel. MFDS promoted the reforms again on 19 October 2026.

What to do. If you plan a first-of-its-kind device filing in Korea, request the pre-submission meeting before you file.

All devicesRegistration route
Sources (2) · verified against the instrument 19 Oct 2026
Read the analysis →
China
In force
In force: 1 Jun 2026

China: rules for class changes, and foreign registrants can propose them through their agent

NMPA Announcement 2026 No. 52 (29 May 2026) sets how registration and filing work when a product's class or regulatory status changes, including pending applications, renewals and transitions; after any transition ends, a product without the right registration or filing cannot be made, sold or imported. Announcement 2026 No. 53 revises the procedure for changing the catalog: a foreign registrant can propose a change through its China agent to the agent's provincial MPA, proposals go to public consultation for at least 30 days, and a move to a higher class normally carries a 2-year transition, or 3 years if a clinical trial is needed.

What to do. If your product is classed higher in China than elsewhere, ask your China agent to file a proposal with the evidence the procedure lists.

All devicesClassification
Sources (2) · verified against the instrument 20 Oct 2026
United Kingdom
Draft
Published: 11 May 2026

Great Britain: draft regulations set out three reliance routes for devices approved in Australia, Canada or the US

The draft Medical Devices (Amendment) Regulations 2026, notified to the WTO, name Australia, Canada and the United States as comparable regulators. Route 1 covers basic Class I devices and non-sterile Class A IVDs with no approved-body review; Route 2 covers devices approved by TGA, by Health Canada at Class III or IV, or by FDA, checked by a UK approved body; Route 3 adds scrutiny for 510(k)-cleared Class IIa, IIb and III devices, software, Class D IVDs and devices with an ancillary medicine. Devices that reached the reference market through reliance, companion diagnostics and some others are excluded. The impact survey closed on 19 June 2026 and no start date has been set.

What to do. If you hold an FDA, TGA or Health Canada approval, map your device to a route now, and note that a 510(k) Class IIa or higher device goes to the higher-scrutiny Route 3.

All devicesReliance & recognitionRegistration route
Sources (3) · verified against the instrument 20 Oct 2026
Saudi Arabia
In force
In force: 3 May 2026

Saudi Arabia: new rules on grouping devices into one marketing-authorization application

SFDA guidance MDS-G28 (version 1.0, 3 May 2026) replaces Annex 15 of the marketing-authorization requirements (MDS-REQ 1). It sets when devices may share one MDMA application as a family, a system, a procedure pack or an IVD group: the same legal manufacturer and, for most groupings, the same risk class and intended use, with at most five technical files and 50 devices per application. IVDs are grouped by principle of operation and listed test categories, and a standalone product cannot be bundled with a kit that contains it. Applications on the reliance route must follow the same rules.

What to do. Map your portfolio against the family, system and pack rules before you budget Saudi filings; the five-file and 50-item limits decide how many applications you need.

All devicesIVDRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
MalaysiaThailand
In force
In force: 1 May 2026

Malaysia and Thailand: the two-way device reliance program moves to full implementation

MDA and Thai FDA announced on 1 May 2026 that, after a pilot from 1 February to 30 April 2026, their reliance program for Class B, C and D devices is fully in place. A Thai-approved device can use MDA's verification route instead of full evaluation. An MDA-approved device can skip Thailand's external expert evaluation, though a full CSDT is still filed. At that date the Thai leg rested on a draft notification; it became law on 6 October 2026.

What to do. If you hold either approval, ask your license holder in the other country to file under the program, and keep the labeling identical between the two.

All devicesIVDReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
Japan
In force
In force: 1 May 2026

Japan: priority review for a US-authorized twin of a Japanese device in shortage

From 1 May 2026 the amended PMD Act allows priority review and priority QMS inspection of an overseas product when a device already approved in Japan is in serious shortage and there is no medically suitable alternative. The overseas product must be identical to the Japanese one and allowed for sale in the United States, the only country named for devices and IVDs. MHLW decides case by case after consultation, and only where a faster partial-change approval cannot fix the shortage. It is not a general fast track for FDA-cleared devices.

What to do. If a Japanese-approved product faces a supply gap, consult MHLW early about importing its US version under this route.

All devicesIVDRegistration routeSupply & shortages
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 1 May 2026

China: new rules for certificates of free sale for devices made in China

NMPA Announcement 2025 No. 126 (24 December 2025) replaces the 2015 export certificate rules from 1 May 2026. Certificate I is for devices registered or filed in China and is requested by the registrant. Certificate II is for devices made in China but not registered there; the actual manufacturer applies, needs a Chinese production license or filing covering that product category, and must show it meets the device GMP. Provinces may inspect, must decide within 20 working days and publish each certificate; electronic certificates are equally valid.

What to do. If a contract manufacturer in China makes your device and a target market asks for a certificate from the country of manufacture, confirm the manufacturer can get Certificate II.

All devicesAdministrativeSupply & shortages
Sources (1) · verified against the instrument 20 Oct 2026
Japan
In force
In force: 1 May 2026

Japan: a revised conditional approval route for devices and IVDs

Since 1 May 2026 MHLW can approve a device or IVD with conditions where it is highly needed and its effect can be reasonably predicted from the clinical data available, under the 2025 amendment of the PMD Act. A new MHLW notice sets two types: highly needed devices for serious conditions with no adequate alternative, and devices that act physically (for example by ablation) whose use can be extended to a new range by extrapolating existing clinical data without a new trial. Eligibility is agreed in a PMDA pre-development consultation; approval comes with a risk management plan, appropriate-use criteria drawn up with the medical societies, and post-market data collection reported yearly. The 2017 conditional early approval scheme for innovative devices and its 2020 notice are abolished.

What to do. If your device treats a serious condition with no good alternative, or extends a physical device to a new range, raise conditional approval at your first PMDA consultation.

All devicesIVDRegistration routePost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
Japan
In force
In force: 1 May 2026

Japan: fewer 30-day reports for device malfunctions abroad

Since 1 May 2026 a marketing authorization holder no longer has to report, within 30 days, a death or serious case abroad from an identical foreign device when the event is foreseeable from the Japanese precautions for use. Instead, a 15-day report is required when such foreseeable deaths or serious cases abroad, or serious cases in Japan, show a trend the precautions do not predict, or a change in trend that signals growing risk. The change comes from the ministerial ordinance implementing the 2025 PMD Act amendment.

What to do. Update your Japanese vigilance procedure so that foreign events are screened for trend changes rather than reported case by case.

All devicesPost-market & vigilance
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 28 Apr 2026

South Korea: no notarized translations for non-English foreign documents

Since 28 April 2026 a full translation of foreign documents in a language other than English no longer has to be notarized: the applicant attaches a confirmation from the manufacturer that the translation is accurate. The same amendment lets real-world evidence replace clinical trial data for device changes, not only for rare or emergency, 3D-printed and AI or big-data devices, and lets a Class 1 device be made or imported in its old form for six months after a change notification.

What to do. If your technical file includes Japanese, German or other non-English documents, have the manufacturer sign off the Korean translation instead of paying for notarisation.

All devicesRegistration routeClinical evidence & trials
Sources (1) · verified against the instrument 20 Oct 2026
United Kingdom
Comment period closed
Comments closed: 10 Apr 2026

Great Britain: MHRA consulted on accepting CE-marked devices indefinitely

The MHRA consulted from 16 February to 10 April 2026 on three proposals: recognizing devices that comply with the EU MDR or IVDR indefinitely; extending acceptance of MDD-certified devices to match the EU dates (for example, to 31 December 2028 instead of 30 June 2028 for Class IIa); and a reliance route for devices classified higher in Great Britain than in the EU. Today CE acceptance is transitional and ends by 30 June 2030 at the latest. No government response has been published yet.

What to do. Keep your CE certificates and UK Responsible Person in place, and do not plan a UKCA conversion for a CE-marked device until the response is out.

All devicesReliance & recognitionRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
United Kingdom
In force
In force: 1 Apr 2026

Great Britain: an annual £300 fee per registered GMDN category from 1 April 2026

SI 2026/197 (made 25 February 2026) raises the device registration fee from £261 to £300 and adds an annual £300 maintenance fee for each registered device, charged once per GMDN Level 2 category: further devices in the same category add nothing. The fee year runs 1 April to 31 March. A company may not place a device on the market while it has unpaid fees.

What to do. Count your chargeable GMDN Level 2 categories and budget the annual fee for each.

All devicesFeesAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
Canada
In force
In force: 1 Apr 2026

Canada: device license applications must go through the regulatory enrollment process from 1 April 2026

Since 1 April 2026 manufacturers must file through the Common Electronic Submission Gateway using the regulatory enrollment process (REP), with submissions in the IMDRF table-of-contents format. This covers Class II to IV license applications and amendments, minor-change faxbacks, private-label licenses, and responses to terms and conditions, information requests and suspensions. Investigational testing, establishment licenses, Special Access and Part 1.1 applications are outside it. A new applicant must file a company template before it can apply.

What to do. File your company template and put your dossier into the IMDRF table-of-contents structure before your next Canadian application.

All devicesAdministrativeRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
Canada
In force
In force: 31 Mar 2026

Canada: new guidance on when a change to a Class III or IV device needs a license amendment

Health Canada's guidance on interpreting 'significant change' (31 March 2026) sets out, with examples, which changes to a licensed Class III or IV device need an amended license before the modified device can be sold. It adds that a change to a Class II device used with a Class III or IV device may need an amendment for the higher-risk device. It does not apply to Part 1.1 urgent-public-health authorizations.

What to do. Run your change-control procedure against the guidance's examples, including changes to Class II companions of Class III or IV devices.

All devicesRegistration routePost-market & vigilance
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 27 Mar 2026

India: CDSCO reminds states that IVF and assisted-reproduction devices need a license

CDSCO found firms selling devices used in in-vitro fertilisation, such as intrauterine insemination kits and centrifuges for sperm washing, without a license under the Medical Devices Rules 2017. Its circular tells state and port authorities to ensure that no such device is imported, made or sold without one. Only Class A non-sterile, non-measuring devices are exempt from licensing.

What to do. If you sell IVF or assisted-reproduction devices in India, confirm each product holds an import or manufacturing license.

All devicesImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
SwitzerlandEuropean Union
Announced
Published: 13 Mar 2026

Switzerland: the Switzerland–EU package that could restore device mutual recognition is signed but not in force

The EU has refused to update the medical-device chapter of the Switzerland–EU Mutual Recognition Agreement since May 2021, so each side treats the other as a third country for devices. The Switzerland–EU package, signed on 2 March 2026 and sent to the Swiss Parliament on 13 March 2026, adds the institutional elements the EU had required for updating the agreement. Until it enters into force and the device chapter is updated, nothing changes: Swiss makers still need an EU authorized representative, and EU makers a CH-REP.

What to do. Keep your CH-REP and EU authorized-representative arrangements in place; there is no date for any change yet.

All devicesReliance & recognition
Sources (2) · verified against the instrument 20 Oct 2026
China
In force
In force: 13 Mar 2026

China: UDI exemptions defined, and how standalone software shows its UDI

NMPA Announcement 2026 No. 15 (23 January 2026, published 13 March 2026) lists cases exempt from UDI: single items inside a UDI-marked sales unit (not implants coded 12 or 13), custom-made devices, kit components used only in the kit, shipping packaging, export-only devices, and drug-led combination products with drug traceability. Reprocessed reusable devices need direct marking where feasible; Class I reusable surgical instruments need only the UDI-DI. Software supplied without a physical medium shows the UDI as plain text on a visible screen, or sends it through an API if it has no user interface.

What to do. If you supply software or reusable instruments in China, build the UDI display or marking into your next release.

Software & AIAll devicesLabelingSoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
SingaporeMalaysia
In force
In force: 10 Mar 2026

Singapore: a Malaysian registration now qualifies for HSA's abridged route

Revision 13 of HSA's GN-15 (10 March 2026) adds a regulatory reliance section. Class B, C and D devices that went through full conformity assessment by an MDA-recognized body and are registered with MDA qualify for the abridged evaluation route, for a labeled use identical to the Singapore one. The MDA registration certificate and the conformity certificate replace proof of a reference-agency approval. Devices with a registrable medicinal product and borderline products classified differently by the two authorities are excluded.

What to do. If Malaysia is your first ASEAN registration, plan Singapore next through the abridged route and keep the labeled use identical.

All devicesIVDReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
Saudi Arabia
In force
In force: 5 Mar 2026

Saudi Arabia: the revised combination-product guide adds a registration process and a phased full-dossier requirement

Version 2.0 of SFDA's Guidance for Combination Products Classification and Registration (implemented 5 March 2026) keeps assignment by primary mode of action and adds a registration process: you file with the leading sector, which may consult the other. For device-led products, a full MDS-REQ 1 technical file plus an ancillary drug dossier is voluntary from 2027 to 2030 and mandatory from 2030; drug-led products need a full eCTD plus the ancillary device requirements on the same timetable. A classification request costs SAR 1,000, is non-refundable and takes 3 working days; an appeal is free and is lodged within 60 days of the decision.

What to do. If you make a drug-device product, request a classification early and start building the ancillary dossier now, so the 2030 requirement does not force a re-filing.

CombinationClassificationRegistration routeFees
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
Draft
Published: 3 Mar 2026

South Korea: draft rule would require prior approval only for significant device changes

MFDS proposed amending the Enforcement Rule so that manufacturers and importers need prior change approval only for significant changes, as set out separately. Other changes would be managed by the company under a change evaluation procedure submitted with the first application, with records kept. The draft would also cut the time to confirm that a conditionally licensed company has met its GMP condition from 20 to 10 days. Comments closed on 13 April 2026; the rule had not been promulgated as at 20 October 2026, by our check of the national law database.

What to do. If you make frequent minor changes to a Korean-licensed device, prepare a written change evaluation procedure now.

All devicesRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
MalaysiaSingapore
In force
In force: 1 Mar 2026

Malaysia: a Singapore registration now leads to a 30-working-day verification

After a pilot from 1 September 2025 to 28 February 2026, MDA accepts Class B, C and D devices listed on Singapore's device register through its verification route from 1 March 2026. HSA states the conformity assessment body review takes 30 working days instead of 60 on the full route, with registration within a further 30 working days. Devices classified differently by MDA and HSA, and Class D devices with an ancillary drug, are excluded.

What to do. If you are registered with HSA, use that registration as the reference for Malaysia and say so in the MeDC@St verification filing.

All devicesIVDReliance & recognition
Sources (2) · verified against the instrument 20 Oct 2026
Brazil
In force
In force: 1 Mar 2026

Brazil: the UDI database is open, which starts the clock for sending device data to ANVISA

Instruction IN 426/2026 opens SIUD, ANVISA's UDI database, from 1 March 2026. The registration holder must send each model's UDI-DI before the device is placed on the Brazilian market; until the deadline for its class, sending is voluntary. Under RDC 591/2021 the deadlines run from this instruction: 3.5 years for Class IV, 4 for Class III, 5 for Class II and 6 for Class I, which by our count (from 1 March 2026) means 1 September 2029 for Class IV and 1 March 2030 for Class III.

What to do. Ask your Brazilian registration holder who will load your UDI-DIs into SIUD, and plan Class IV data first.

All devicesLabelingPost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
Chile
In force
In force: 21 Feb 2026

Chile: blood-grouping and antibody reagents need registration from 21 February 2026

Exempt Decree 5 (signed 4 February, published 21 February 2025 in Diario Oficial 44.081) brings immunohaematology reagents under ISP's mandatory control: ABO and RhD grouping sera, reagent red cells A1, A2, B and O, antibody screening and identification panels, antiglobulin (Coombs) sera, and column and solid-phase agglutination systems. They are grouped in classes C and D and verified against NCh-ISO 16142-2:2021, with minimum sensitivity and specificity of 98%. Each product also needs an ISP first-lot performance evaluation, phased by product group: 12 months after publication for grouping sera, ABO-RhD agglutination systems and reagent red cells, 24 months for antibody panels, and 36 months for antiglobulin products (by our count 21 February 2026, 2027 and 2028). The decree took effect 12 months after publication, on 21 February 2026 per ISP. A later change to the design, intended use, components, performance or labeling must be notified to ISP.

What to do. If you sell these reagents in Chile, they need a registration now; check when your product group's first-lot evaluation starts.

IVDRegistration routeClassification
Sources (2) · verified against the instrument 27 Oct 2026
Argentina
In force
In force: 15 Feb 2026

Argentina: Class I and II devices authorized in a listed country can be registered by sworn notification

Decree 892/2025 (published 17 December 2025, in force 60 days later, by our count 15 February 2026) and ANMAT Disposición 236/2026 (published 6 February 2026) cover foreign-made Class I and II devices and Class A and B IVDs that need no cold chain. These are registered by a sworn declaration with prior-notification status on ANMAT's systems, and are exempt from local testing if they are authorized and marketed in a country listed in Annex I of the decree, shown by a certificate of free sale no older than 24 months. Otherwise accredited certificates or test reports can be used, or the product goes through ordinary registration. Only an importer licensed by ANMAT can use the route.

What to do. For Class I or II products, get a current certificate of free sale from a listed country and have your licensed importer file the notification.

All devicesIVDReliance & recognitionRegistration routeImport & licensing
Sources (2) · verified against the instrument 20 Oct 2026
TaiwanUnited States
Announced
Published: 13 Feb 2026

Taiwan: the US trade agreement promises faster review for US-made, FDA-authorized devices

Taiwan and the United States signed the Agreement on Reciprocal Trade on 12 February 2026 (US time). Taiwan's Executive Yuan says Taiwan will accept FDA marketing authorization of US-made devices and medicines as sufficient evidence for its own review, to speed that review up. It applies only to products made in the United States. The agreement goes to the Legislative Yuan for review, and we found no TFDA implementing notice as at 20 October 2026.

What to do. If you make devices in the United States, keep your FDA authorization documents ready for Taiwan, but plan on a full TFDA review until an implementing notice appears.

All devicesReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 2 Feb 2026

United States: the Quality Management System Regulation, built on ISO 13485, applies from 2 February 2026

The QMSR final rule of 2 February 2024 replaced the device quality system requirements in 21 CFR 820 by incorporating ISO 13485:2016 by reference, with additional FDA requirements, effective 2 February 2026. Technical amendments published in December 2025 updated cross-references in 179 sections of the device regulations and add no new requirements. A draft guidance of 17 November 2025 sets out the quality-system information FDA expects in certain premarket submissions under the QMSR; comments closed on 16 January 2026.

What to do. Map your ISO 13485 system against the QMSR's added requirements, and update procedures and records that still cite the old Quality System Regulation.

All devicesQMS & GMP
Sources (3) · verified against the instrument 20 Oct 2026
Japan
In force
In force: 30 Jan 2026

Japan: clearer rules on when a change of material needs only a minor-change notification

A new MHLW notice replaces the 2013 rules on changing a device's materials. A material change that does not affect quality, efficacy or safety can be made by minor-change notification instead of a partial-change application. It applies to materials in direct or indirect contact with the body; for implanted parts, long-term contact parts, biological, biodegradable and functional coating materials it applies only where low risk is shown, for example by prior approvals at home or abroad or clinical use. Very brief-contact, sealing, colouring and mechanical-part materials may be listed by generic name only.

What to do. Before your next material change in Japan, check it against the new notice; it may need only a notification.

All devicesRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 24 Jan 2026

South Korea: voluntary reporting and performance certification for digital wellness products

Since 24 January 2026 makers and importers of digital medical and health-support devices can report them to MFDS and apply for performance certification. These are digital products that are not medical devices but monitor or analyze biosignals, or record lifestyle data to give health management information, as designated by MFDS. Both steps are voluntary; certified products may carry an MFDS mark and are listed on MFDS's website. MFDS can order recall, replacement, destruction or a sales stop where such a product seriously endangers health.

What to do. If you sell a wellness wearable or app in Korea, decide whether performance certification is worth having as a marketing claim.

Software & AISoftware & AI rulesRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
United States
In force
In force: 6 Jan 2026

United States: FDA revises its guidance on when decision-support and wellness software are not devices

FDA issued revised final guidances on 6 January 2026; the clinical decision support guidance was re-issued on 29 January. It says FDA intends to exercise enforcement discretion where software otherwise meets the non-device criteria but gives a single recommendation because only one option is clinically appropriate; software that analyses images or signals stays a device. The general wellness guidance, replacing the 2019 version, says a non-invasive product that estimates values such as blood pressure, oxygen saturation or glucose can be a wellness product when the output is solely for wellness, but not when it is meant for screening, diagnosis, monitoring or alerting.

What to do. Re-check your software's device status against the January 2026 texts before deciding whether a US submission is needed.

Software & AISoftware & AI rulesClassification
Sources (2) · verified against the instrument 20 Oct 2026
China
In force
In force: 4 Jan 2026

China: 31 entries in the device classification catalog changed

NMPA Announcement 2025 No. 132 (30 December 2025, published 4 January 2026) changes 31 entries in the Medical Device Classification Catalog, including descriptions, intended uses, examples and, for some products, the class. New applications follow the new class at once; pending ones finish under the old class with the new class noted. A certificate moving from Class III to II stays valid, and renewal is made under the new class at least six months before expiry; a Class II certificate moving to Class I stays valid until expiry, then the product is filed.

What to do. Check the adjustment table for your product codes and time your renewal to the new class.

All devicesClassification
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 3 Jan 2026

South Korea: MFDS performance evaluation of IVDs on the market

From 3 January 2026 MFDS can carry out performance evaluations of approved, certified or notified IVDs, and of IVDs under emergency use authorization. A company can apply for an evaluation and may be charged its cost; the work can be delegated to clinical performance testing institutions. If an evaluation shows a risk to public health, MFDS can order manufacture, import or sale stopped. A draft notice on evaluation criteria and methods was consulted on until 4 June 2026.

What to do. Make sure the accuracy, precision and sensitivity claims in your Korean IVD files can be reproduced by an independent laboratory.

IVDPost-market & vigilance
Sources (3) · verified against the instrument 20 Oct 2026
Ukraine
In force
In force: 1 Jan 2026

Ukraine: one agency now buys everything for the army, including medical supplies

Since 1 January 2026 all purchases for Ukraine's army run through a single buyer, the Defence Procurement Agency DOT, a state enterprise of the Ministry of Defence. Before, the State Rear Operator bought rear supplies, including medical property, and the Defence Procurement Agency bought weapons and military equipment. The two were merged by Ministry of Defence order No. 281 of 2 May 2025. This is a change of buyer, not of the rules a device must meet.

What to do. If you sell trauma or field-care devices to Ukraine's armed forces, the contract is with the Defence Procurement Agency DOT. The rules your device must meet in Ukraine are unchanged.

All devicesSupply & shortages
Sources (2) · verified against the instrument 4 Nov 2026
China
In force
In force: 24 Dec 2025

China: a list of high-end devices that get priority review

NMPA Notice 2025 No. 48 (24 December 2025) publishes the Priority Approval High-end Medical Devices Catalog (2025), which implements Announcement 2025 No. 63. Registration applications for listed devices get priority review under Article 73(3) of the Registration and Filing Measures. CMDE checks each application, publishes the result and, if there is no objection, moves it into the priority procedure; otherwise it follows the normal route. NMPA says it will update the list.

What to do. Check whether your device falls in a category on the list, and ask for priority when you file.

All devicesRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 19 Dec 2025

China: websites and apps that give device information must be filed with the province

NMPA Announcement 2025 No. 123 (19 December 2025) sets filing rules for providing drug and device information on the internet in China, in force on publication. Each website, app or client is filed with the provincial MPA before the service starts. The provider must be a lawfully established organization with at least two qualified drug or device technical staff, must show the filing number on its home page, and must update the filing within 30 days of a change. The province checks the filing within three months.

What to do. If you, your agent or your Chinese subsidiary runs a Chinese-language site or app with product information, check that it carries a filing number.

All devicesAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
European Union
Draft
Published: 16 Dec 2025

European Union: a proposal would move medical devices to the AI Act's lighter Annex I Section B

The Commission's proposal to revise the MDR and IVDR (COM(2025) 1023, Article 4) would move both regulations from Section A to Section B of the AI Act's Annex I. It is still in the Parliament committee; an indicative plenary date is 14 December 2026.

What to do. Keep planning to the 2 August 2028 date that is in force, and watch the December plenary.

Software & AIIVDSoftware & AI rules
Sources (1) · verified against the instrument 19 Oct 2026
Read the analysis →
Philippines
In force
Published: 16 Dec 2025

Philippines: Class A device notifications move to the FDA eServices portal

FDA Circular 2025-007 (16 December 2025) moves initial applications for a Certificate of Medical Device Notification (CMDN), the authorization for every Class A device, from the old ePortal to the eServices Portal, which needs no account or password. Filing on the ePortal stops when the circular takes effect, 15 days after publication; applications already filed there are processed there. Requirements are unchanged (AO 2018-0002). Renewals and variations are not covered: they still go to the FDA Action Center by email until a separate guideline is issued.

What to do. File new Class A notifications on the eServices portal; send renewals and variations by email for now.

All devicesAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
Philippines
In force
Published: 16 Dec 2025

Philippines: FDA portal accounts are now created online and lapse after a year without use

FDA Circular 2025-006 (16 December 2025) makes the eServices Portal the only place to create or renew a user account for the FDA's other portals: the older ePortal (still used for manufacturers' Licenses to Operate), ePortal2 (cosmetics and household hazardous substances) and the RRDPortal (radiation facilities). Accounts are issued automatically, with no manual confirmation, and are valid for two years. An account under which no licensing, registration or notification application is filed within one year of issue expires, and a new registration is then needed. Accounts issued before the circular stay valid. It repeals FDA Circular 2023-006, FDA Circular 2020-033, FDA Circular 2016-004 and FDA Advisory 2020-1929, and took effect on posting and publication.

What to do. If you or your local license holder use the ePortal or RRDPortal, check the account's issue date: file within a year or expect to re-register.

All devicesAdministrative
Sources (1) · verified against the instrument 21 Oct 2026
Philippines
In force
In force: 10 Dec 2025

Philippines: new rules for compassionate use of unregistered devices

Administrative Order 2025-0024 replaces the 1992 compassionate special permit rules and covers medical devices and medical equipment. A qualified institution or licensed physician can obtain a permit for a named patient or for institutional use, to treat HIV/AIDS, cancer, life-threatening conditions, declared public-health emergencies, conditions causing permanent disability, or rare diseases. A device without Philippine registration qualifies only if it is registered in its country of origin or by another national regulator, and used or refurbished devices are excluded. The permit is not a marketing authorization; the FDA lists 10 December 2025 as the effective date.

What to do. If a Philippine hospital wants your device before registration, it can apply for a permit; have your home-country approval ready.

All devicesRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
AustraliaUnited Kingdom
In force
In force: 1 Dec 2025

Australia: UK approved bodies become comparable overseas regulators

From 1 December 2025 a UK approved body is listed as an overseas regulator for subsection 41BIB(1) of the Therapeutic Goods Act. Evidence it issued can now support ARTG inclusion, alongside notified bodies, MDSAP auditing organizations, Health Canada, HSA, Japan's MHLW and PMDA, and the US FDA.

What to do. If your device holds a UKCA certificate, ask your Australian sponsor to use it as conformity evidence.

All devicesIVDReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 27 Nov 2025

India: ask CDSCO online for the risk class of a device that is not on its lists

CDSCO opened a risk-classification module on its online device portal for devices other than IVDs on 27 November 2025, and for IVDs on 2 February 2026. An applicant whose device is not on CDSCO's published classification lists can apply there for a class under the Medical Devices Rules 2017.

What to do. If your device is not on a CDSCO list, get its class through the portal before you file a license application.

All devicesIVDClassification
Sources (2) · verified against the instrument 20 Oct 2026
Saudi Arabia
In force
In force: 17 Nov 2025

Saudi Arabia: radioactive medical materials need SFDA specification approval per import, and an MDMA where they are devices

SFDA's MDS-REQ 6 was retitled and expanded in version 2.0 (17 November 2025; the current version 2.1 is dated 7 January 2026). The importer files each request in SFDA's MRMR system for approval of the technical and clinical specifications before the Nuclear and Radiological Regulatory Commission licenses the activity, and each approval letter serves one application only. Radioactive materials classified as medical devices must hold a marketing authorization (MDMA); those classified as drugs need drug registration. Transporters of these materials are now in scope.

What to do. If you supply a radioactive product classified as a device to Saudi Arabia, confirm it holds an MDMA and that your importer is registered in MRMR before the next shipment.

ImplantableActive (powered)Import & licensing
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 17 Nov 2025

India: CDSCO tells hospitals and buyers to require the Indian license in device tenders

CDSCO noted that hospitals and procurement agencies were asking for US FDA or CE certification in technical bids. Its circular asks all procurement agencies, hospitals and health institutions to make the CDSCO or state license mandatory in device procurement, and says any other certification they ask for comes on top of that license, not instead of it.

What to do. Before you bid in an Indian tender, make sure your import or manufacturing license is in hand; FDA or CE status is not a substitute.

All devicesImport & licensingHTA & reimbursement
Sources (1) · verified against the instrument 20 Oct 2026
Mexico
In force
In force: 12 Nov 2025

Mexico: an MDSAP audit counts as meeting the quality-system part of the device GMP standard

COFEPRIS's interpretation criterion for NOM-241-SSA1-2025 (device good manufacturing practice), published 11 November 2025 and in force the next business day (by our count 12 November), recognizes MDSAP compliance and MDSAP audit reports as meeting the standard's quality-system requirements for any manufacturing site, without further inspections or audits. For registrations, renewals and changes, an applicant may file a Mexican GMP certificate or an equivalent document. It builds on the March 2025 guidelines that accepted the MDSAP certificate as GMP evidence.

What to do. If your plants are MDSAP-certified, file that certificate as your GMP evidence in Mexico instead of waiting for a COFEPRIS inspection.

All devicesQMS & GMPReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
In force: 9 Nov 2025

European Union: procedural rules for joint clinical assessment of devices, with a 100-day dossier deadline

Implementing Regulation (EU) 2025/2086 (17 October 2025) sets how a device's joint clinical assessment runs: the developer submits the dossier within 100 days of the Commission's first request, supplies missing information within 15 days of a second request, and can ask for a scope-explanation meeting. Only Class IIb and III devices with an expert-panel opinion and Class D IVDs with expert-panel views can be selected. It entered into force 20 days after publication on 20 October 2025, by our count 9 November 2025.

What to do. If your device will go through the expert-panel consultation, plan the joint-assessment dossier alongside the clinical evaluation so you can meet 100 days.

ImplantableActive (powered)IVDHTA & reimbursementClinical evidence & trials
Sources (2) · verified against the instrument 20 Oct 2026
Brazil
In force
In force: 4 Nov 2025

Brazil: nasal-wash saline products are now regulated as Class IV medical devices

RDC 996/2025 moves sodium chloride powders for making solutions, and 0.9% saline solutions, used to wash the nasal cavity into the medical device category, in risk Class IV under rule 14 of RDC 751/2022. Products with decongestant or wound-wash claims, or for nebulisation, are excluded. A medicines GMP certificate for an equivalent dosage form can stand in for the device GMP certificate. It took effect on 4 November 2025.

What to do. If you sell a nasal-wash saline product in Brazil, plan its re-registration as a Class IV device.

Non-activeClassification
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 1 Oct 2025

United States: De Novo requests must be filed through eSTAR from 1 October 2025

FDA's final guidance on the electronic submission template for De Novo requests (August 2024) sets the standards, timetable and waiver criteria for filing De Novo requests electronically. From 1 October 2025 FDA requires De Novo requests to be submitted as the guidance describes, in the eSTAR template.

What to do. Build a De Novo request in eSTAR from the start rather than converting a finished dossier.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 1 Oct 2025

China: good practice for selling devices online applies from 1 October 2025

NMPA Announcement 2025 No. 46 (28 April 2025) sets quality management rules for anyone selling devices online and for e-commerce platforms, from 1 October 2025. Sellers must show the registration certificate on the product page, with numbers as text, and the product name, registrant, manufacturer, import agent, models and intended use must match the certificate and labeling. Servers for a seller's own website or app must be in China, and records must carry the online order number. NMPA's inspection guidance of 25 September 2025 sets pass, rectify and fail thresholds.

What to do. If your devices are sold online in China, by you, your agent or distributors, check that every listing matches the registration certificate.

All devicesSupply & shortagesPost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
Malaysia
In force
In force: 30 Sep 2025

Malaysia: a device approved by a recognized authority goes through verification, with no one-year marketing rule

Circular Letter No. 2 of 2025 (30 September 2025, effective on issue) sets the policy: a device approved by an authority listed in Appendix 1 of guidance MDA/GD/0068 needs only conformity assessment by verification, done by an MDA-registered conformity assessment body, instead of a full assessment. The second edition of GD/0068 (8 September 2025) removed the condition that the device had been marketed for at least a year in the reference jurisdiction. Devices authorized only through special schemes are excluded, and for the US only 510(k) clearance and PMA are listed, not De Novo.

What to do. If you hold a CE (notified body), TGA, Health Canada, Japanese or US 510(k)/PMA approval, ask your Malaysian authorized representative to file through verification, even if the product is newly launched.

All devicesIVDReliance & recognitionRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
Nigeria
In force
In force: 25 Sep 2025

Nigeria: a reliance procedure for devices and IVDs approved by stringent authorities

NAFDAC's reliance guideline (DR&R-GDL-035-01, effective 25 September 2025) covers medical devices and IVDs as well as drugs. A product registered for more than six months by a stringent regulatory authority as WHO defines it (the US, the EU, Japan, Switzerland and Canada, plus Australia, Iceland, Liechtenstein and Norway), and the same as the product filed, gets an abridged review with a decision within 60 working days. The applicant must supply complete, unredacted assessment reports and free-sale and GMP certificates authenticated by a Nigerian embassy, and NAFDAC may still test samples and categorise the plant by GMP risk.

What to do. If you hold a qualifying approval more than six months old, find out now whether you can obtain the unredacted assessment report the route depends on.

All devicesIVDReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
United States
In force
In force: 19 Sep 2025

United States: FDA removes its laboratory-developed test rule after a court vacated it

On 31 March 2025 a federal district court vacated FDA's May 2024 rule, which had added laboratories to the definition of IVD manufacturers. A final rule published and effective on 19 September 2025 deletes the words 'including when the manufacturer of these products is a laboratory' from 21 CFR 809.3(a), restoring the earlier text. On our reading, the 2024 rule's phased timetable for laboratories no longer applies.

What to do. If your US plan assumed laboratory-developed tests would need FDA authorization under the 2024 rule, revisit the competitive and regulatory assumptions.

IVDRegistration routeClassification
Sources (1) · verified against the instrument 20 Oct 2026
Malaysia
In force
In force: 16 Sep 2025

Malaysia: MDSAP certificates now count as quality-system evidence

MDA became an MDSAP affiliate member on 16 September 2025 and now accepts MDSAP audit reports and certificates as evidence of quality-system compliance. Foreign manufacturers can use reports from an MDSAP-recognized auditing organization for device registration. Local manufacturers can also use them for the establishment license, but only if the audit was done by an MDA-registered conformity assessment body and auditor.

What to do. If you hold an MDSAP certificate, file it as your QMS evidence in the Malaysian registration.

All devicesQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
India
In force
In force: 11 Sep 2025

India: a separate online application for a second importer of an already-approved device

Since 11 September 2025, CDSCO's online portal has a separate application for a "subsequent importer": another importer of a device or IVD that CDSCO has already approved for import. It follows a dedicated checklist. CDSCO's IVD FAQ says this applies where the legal and actual manufacturing sites are the same as in the existing license.

What to do. If you add or switch Indian importers, use the subsequent-importer application rather than a fresh import application.

All devicesIVDImport & licensing
Sources (2) · verified against the instrument 20 Oct 2026
Egypt
In force
In force: 1 Sep 2025

Egypt: the 2025 edition of EDA's import registration guide keeps the reference-country basis and adds Croatia and Liechtenstein

The Egyptian Drug Authority reissued its guideline for registering imported and local devices that hold international quality certificates (EDREX:GL.CAMD.002; its history table records 22 July 2025, then version 2 on 1 September 2025, which renamed the inspection departments). It lists 37 reference countries; the 2021 edition, still on EDA's site, listed 35, without Croatia and Liechtenstein. A free-sale certificate from a reference country, or an FDA Certificate to Foreign Government, remains the basis for registration, and reference-country certificates need no consular legalization when EDA can verify them with the issuer. Registration is valid for ten years.

What to do. If your free-sale certificate comes from Croatia or Liechtenstein, Egypt now lists it as a reference country; otherwise nothing changes in how you file.

All devicesReliance & recognitionImport & licensing
Sources (2) · verified against the instrument 20 Oct 2026
Mexico
In force
In force: 29 Aug 2025

Mexico: an abbreviated registration route for devices approved by an IMDRF Management Committee member

Guidelines published in the Diario Oficial on 18 July 2025, in force 30 business days later (by our count 29 August 2025), let COFEPRIS register a device that is the same as one approved by a reference authority. For devices the reference authorities are the members of the IMDRF Management Committee, and MDSAP full members for GMP certificates. COFEPRIS checks only that the dossier is complete and has 30 business days to decide (procedure COFEPRIS-04-050). It still assigns the Mexican risk class.

What to do. If you hold an approval from an IMDRF Management Committee member, file on this route with the reference dossier and a Spanish label and instructions.

All devicesIVDReliance & recognitionRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
Taiwan
In force
In force: 14 Aug 2025

Taiwan: revised registration guidance for AI detection and diagnosis software, with a standalone performance FAQ

TFDA revised its registration guidance for AI and machine-learning computer-aided detection (CADe) and diagnosis (CADx) devices, replacing the September 2023 version. A new FAQ explains standalone performance assessment, meaning testing on existing labeled data without new reading by clinicians. Where a similar product is already licensed in Taiwan, clinical evidence may be waived; for a device with no similar product, standalone testing alone is not enough and clinical evidence is needed.

What to do. If you are filing AI imaging software in Taiwan, check whether a similar product is licensed before you decide what clinical evidence to bring.

Software & AISoftware & AI rulesClinical evidence & trials
Sources (1) · verified against the instrument 20 Oct 2026
Saudi Arabia
In force
In force: 11 Aug 2025

Saudi Arabia: where wellness apps and wearables end and medical devices begin

Two SFDA guidances set the line: General Wellness Devices (MDS-G25, 12 March 2025) and Digital Health Products (MDS-G27, 11 August 2025), which covers SaMD, apps, digital therapeutics, wearables, VR/AR and AI. A wellness claim, even one that names a chronic disease such as type 2 diabetes, stays outside device rules if it is about living well with the condition rather than diagnosing or treating it. Two Saudi-specific edges: a wellness product that is invasive, implanted or uses a technology that can pose a risk needs an MDMA even with no medical claim, and once the maker knows clinicians use it for a medical purpose it is treated as a device. MDS-G27 requires wellness labeling, in Arabic and English, stating the product is not for medical use.

What to do. Check your app's or wearable's claims against both guides before launch, and add the Arabic and English not-for-medical-use statement if you sell it as wellness.

Software & AIActive (powered)Software & AI rulesClassificationLabeling
Sources (2) · verified against the instrument 20 Oct 2026
Japan
In force
In force: 8 Aug 2025

Japan: evaluation criteria for home-use software that treats disease

MHLW published evaluation criteria for home-use program medical devices that treat disease, including apps adapted from software used in clinics. The criteria set out the data and review points expected in an approval application. They are not legal standards: items may be added or left out depending on the product, and MHLW advises early PMDA consultation.

What to do. If you are developing a patient-facing therapeutic app for Japan, build your evidence plan against these criteria.

Software & AISoftware & AI rulesClinical evidence & trials
Sources (1) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 1 Aug 2025

South Korea: long-term follow-up with real-world data for pacemakers, breast implants and hip joints

An amendment to the Medical Devices Act, in force from 1 August 2025, lets MFDS designate devices that need long-term follow-up because serious or frequent adverse events are a concern, and collect and analyze real-world data on them. A notice of 20 August 2025 designated implantable pacemakers (including leads), breast implants and hip joints. Participating clinicians register with the system and submit usage and adverse-event data to the Korea Medical Device Safety Information Institute every half-year, or at once after a serious event.

What to do. If you supply these implants in Korea, expect real-world safety signals from the follow-up program and plan how you will respond to them.

ImplantablePost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
Brazil
In force
In force: 29 Jul 2025

Brazil: ANVISA can grant or renew a GMP certificate on risk analysis and foreign reports, without an inspection every time

RDC 982/2025 covers GMP certificates (CBPF) for medicines, biologicals and medical devices. ANVISA may grant or renew one by analysing an inspection report from an equivalent foreign authority, by risk analysis, or by an inspection that the risk analysis triggers; its criteria include MDSAP audit reports and IMDRF members' inspection reports. The rule took effect on 29 July 2025, but each mechanism applies only once ANVISA's Board approves it. Since July 2026 (RDC 1.032) ANVISA may also take a petition out of date order when the same site already has an inspection scheduled or is tied to a registration under review.

What to do. If your plant has an MDSAP report, file it with your CBPF petition, and ask your Brazilian holder whether the Board has approved the risk-based route for devices yet.

All devicesQMS & GMPReliance & recognition
Sources (2) · verified against the instrument 20 Oct 2026
Nigeria
In force
In force: 25 Jul 2025

Nigeria: NAFDAC's emergency use authorization covers devices, and national-security incidents count

NAFDAC's Guidelines for Emergency Use Authorization for Medical Products (DR&R-GDL-008-01), effective 25 July 2025, cover unlicensed vaccines, therapeutics and medical devices including IVDs. They apply primarily during declared public health emergencies, and the emergencies they describe include "any incident with a significant potential to affect national security".

What to do. If your device is not yet registered in Nigeria, an EUA is possible only in a declared emergency. Plan the ordinary registration in parallel.

All devicesIVDRegistration route
Sources (1) · verified against the instrument 2 Nov 2026
Argentina
In force
In force: 24 Jul 2025

Argentina: ANMAT no longer authorizes each import of Class I and II devices

Disposición 4446/2025 (published 24 June 2025, in force 30 days later, by our count 24 July 2025) ends ANMAT's authorization of each import of Class I and II devices, for sale or free distribution, by importers it has licensed. Instead the importer files an import notice, as a sworn declaration on the TAD platform, within 48 hours of customs clearance. The change covers only Class I and II, and importers and products must still meet ANMAT's device rules.

What to do. Make sure your Argentine importer files the 48-hour import notice for Class I and II shipments.

All devicesImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
In force: 16 Jul 2025

European Union: electronic instructions for use allowed for all devices meant for professional users

Implementing Regulation (EU) 2025/1234 (25 June 2025) extends the electronic-IFU rules to every MDR device and accessory intended for professional users, including legacy devices and Annex XVI products for professional use. Before, only certain device types qualified. Where lay people may reasonably use the device too, their instructions must still be on paper. It entered into force 20 days after publication on 26 June 2025, by our count 16 July 2025.

What to do. If your devices are for professional use, check whether switching to electronic IFU cuts printing and translation cost, and keep paper for any lay-user instructions.

All devicesLabeling
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 6 Jul 2025

China: EU companies excluded from large government device tenders

Ministry of Finance notice Caiku [2025] No. 19, in force from 6 July 2025, applies to government procurement of listed device types with a budget of RMB 45 million or more where imported products are needed. EU companies are excluded, and other suppliers' EU-made devices may not exceed 50% of the contract value. EU-invested companies registered in China may bid, and devices they make in China are not restricted. The ministry's Q&A says origin follows the customs declaration, and the measure does not cover state-owned enterprise purchasing or the health-insurance volume-based procurement of consumables.

What to do. If you sell EU-made capital equipment into Chinese public hospitals, check which tenders cross RMB 45 million and how your bid is built.

All devicesHTA & reimbursement
Sources (2) · verified against the instrument 20 Oct 2026
Israel
Draft
Deadline passed: 1 Jul 2025

Israel: draft regulations would register devices approved in recognized countries by risk tier, Class I on a declaration

The Health Ministry published a draft amendment to the 2013 regulations on registering medical equipment in the register, open for public comment from 10 June to 1 July 2025. For equipment registered and marketed in recognized countries it proposes immediate registration on a declaration for low-risk (Class I) equipment, fast registration within 45 working days for medium risk and within 60 working days for medium-to-high risk. We have not confirmed whether the amendment has since been made.

What to do. Until the amendment is confirmed in force, plan Israeli filings on the existing fast-track procedure.

All devicesReliance & recognitionRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
Published: Jun 2025

European Union: revised guidance on whether software is a medical device and how Rule 11 classifies it

MDCG 2019-11 rev.1 (June 2025) is the first revision of the core EU guidance on qualifying and classifying software. It stresses writing a clear intended purpose, adds examples including software intended to treat, clarifies Rule 11(a) with examples of software intended to prevent the risk of illness, expands the section on modules, updates the electronic health record example for the European Health Data Space Regulation, and adds a Class I example.

What to do. Re-read your software's intended purpose and Rule 11 rationale against the revised examples before your next notified-body review.

Software & AISoftware & AI rulesClassification
Sources (1) · verified against the instrument 20 Oct 2026
European Union
In force
Published: Jun 2025

European Union: joint guidance on how the AI Act applies to AI medical devices

MDCG 2025-6 / AIB 2025-1 (June 2025), endorsed by both the device and AI boards, explains that an AI medical device is high-risk under Article 6(1) of the AI Act when it needs a notified body under the MDR or IVDR: Class IIa and above, sterile, measuring or reusable-surgical Class I, sterile Class A IVDs and Class B, C and D IVDs. Plain Class I devices, non-sterile Class A IVDs and in-house devices are not high-risk on that basis. It expects a single set of technical documentation covering both laws. It is not legally binding.

What to do. If your AI device needs a notified body, build the AI Act requirements into the same technical file and QMS rather than a parallel one.

Software & AIIVDSoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
China
Announced
In force: 27 Jun 2025

China: NMPA measures to support high-end devices, including simpler AI change registration

NMPA Announcement 2025 No. 63 (27 June 2025), on surgical robots, advanced imaging, AI devices and new biomaterials, keeps innovative special review and extends it to changes of innovative devices. For AI, NMPA says it will simplify change registration where the core algorithm is unchanged and only performance improves, and simplify review of the same AI software function registered on different platforms if equivalence is shown. Most measures are commitments that still need guidance.

What to do. If you hold or plan an AI device registration in China, watch for the change-registration guidance before you plan a full re-review for an algorithm update.

Software & AIActive (powered)ImplantableRegistration routeSoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
United Kingdom
In force
In force: 16 Jun 2025

Great Britain: stronger post-market surveillance rules apply from 16 June 2025

The Medical Devices (Post-market Surveillance Requirements) (Amendment) (Great Britain) Regulations 2024 (SI 2024/1368, made 16 December 2024) insert new post-market surveillance requirements into the Medical Devices Regulations 2002. They came into force 6 months after they were made, on 16 June 2025, and apply to devices placed on the market in Great Britain, including CE-marked devices.

What to do. Make sure your GB post-market surveillance plan, reports and incident timelines follow the 2024 Regulations, not only the EU MDR.

All devicesPost-market & vigilance
Sources (1) · verified against the instrument 20 Oct 2026
Philippines
In force
In force: 10 Jun 2025

Philippines: the FDA's new fee schedule stays suspended, and the 2001 fees apply

Administrative Order 2024-0016 set a new schedule of FDA fees and charges for every health product under the FDA's jurisdiction, medical devices included. Department Circular 2025-0240 (10 June 2025) suspended it; while it is suspended, the fees and authorization validity periods of AO 50 s. 2001 and the other earlier issuances apply, and fees already paid under the new schedule stand. The suspension was extended by DC 2025-0382 and DC 2025-0574, and again by DC 2026-0329 (8 June 2026, effective 9 June 2026) for 120 working days or until the State of National Energy Emergency declared under Executive Order 110 is lifted, whichever is longer.

What to do. Budget Philippine filings on the 2001 fee schedule for now, and check before each filing whether the suspension has been lifted.

All devicesFees
Sources (3) · verified against the instrument 20 Oct 2026
Brazil
In force
In force: 9 Jun 2025

Brazil: ANVISA's import controls move to the single foreign-trade portal

RDC 977/2025 sets out how ANVISA controls imports and exports of goods under sanitary control, by customs code, through the single foreign-trade portal (Duimp declarations and LPCO licenses). Imports declared through Duimp no longer need ANVISA's authorization before shipment abroad. The rule replaced RDC 807/2023 and the pre-shipment section of RDC 81/2008, and took effect on 9 June 2025.

What to do. Check that your importer files through Duimp and has your products in its product catalog.

All devicesImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 12 May 2025

China: new 2025 lists of devices exempt from clinical evaluation and IVDs exempt from clinical trials

NMPA Notice 2025 No. 19 (12 May 2025) replaced the 2023 list of devices exempt from clinical evaluation, and Notice 2025 No. 23 (23 June 2025) replaced the 2021 list of IVDs exempt from clinical trials. Both took effect on publication. Entries in the device list carry conditions, typically that the product is equivalent to one already registered in China and uses established materials.

What to do. Check your product against the 2025 lists before you budget Chinese clinical evidence; an exemption still needs the equivalence the entry describes.

All devicesIVDClinical evidence & trialsRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
China
In force
In force: 1 May 2025

China: revised inspection points for device clinical trials, with refusal for data authenticity problems

NMPA Announcement 2025 No. 22 (28 February 2025) revised the key points and judgment rules for inspecting device and IVD clinical trial projects, from 1 May 2025. For an application under review, an authenticity finding or a serious non-compliance leads to refusal of registration; a lesser 'normative' finding lets the review continue. For a product already registered, an authenticity finding is handled under Article 83 of the Regulation, and a serious non-compliance triggers a risk review. It replaces the 2016 and 2018 inspection documents.

What to do. If you run or rely on a Chinese clinical trial, audit the site's records against the new inspection points before filing.

All devicesIVDClinical evidence & trials
Sources (1) · verified against the instrument 20 Oct 2026
Nigeria
In force
In force: 29 Apr 2025

Nigeria: WHO-prequalified IVDs and devices can register through the WHO collaborative procedure

NAFDAC's guideline VBM-R&RA-GDL-014-00 (effective 29 April 2025) lets the holder of a WHO prequalification for an IVD or other medical device register in Nigeria through WHO's Collaborative Registration Procedure, with WHO sharing its assessment and inspection outputs. The product must be the same as the one prequalified, and NAFDAC decides within 60 working days.

What to do. If your IVD is WHO-prequalified, use this route for Nigeria and consent to WHO sharing your assessment with NAFDAC.

IVDAll devicesReliance & recognition
Sources (1) · verified against the instrument 20 Oct 2026
United States
Draft
Deadline passed: 7 Apr 2025

United States: FDA draft guidance on what a submission for an AI-enabled device should contain

Draft guidance published on 7 January 2025 recommends the content of marketing submissions for devices with AI-enabled software functions and proposes design, development and documentation practices across the product life cycle, including transparency to users. Comments closed on 7 April 2025. On 20 October 2026 FDA's guidance page still listed it as a draft, not for implementation.

What to do. Use the draft as a checklist for an AI device submission, but do not treat it as a binding requirement.

Software & AISoftware & AI rulesRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
Kenya
In force
Published: 7 Apr 2025

Kenya: three reliance routes for devices and IVDs, with Saudi Arabia among the reference authorities

The Pharmacy and Poisons Board's reliance guideline (HPT/PER/GUD/091, January 2025, posted 7 April 2025) sets abridged (60 working days for Class B, 90 for C and D), expedited (30 working days, Class C and D) and immediate (14 working days) routes for devices approved by a listed reference authority: Australia, Canada, Japan, the US (510(k) or PMA), EU notified bodies under the MDR or IVDR, Ireland, Switzerland and Saudi Arabia. Class A gets no reliance. The guideline contradicts itself on some points, including which classes may use the immediate route and whether one or two reference approvals are needed. PPB's April 2025 umbrella reliance guideline (HPT/PER/GUD/034) confirms this document governs reliance-based marketing authorization.

What to do. A Saudi MDMA or a US 510(k) can shorten a Kenyan filing; confirm with PPB through your local agent which route your class qualifies for before you set a timeline.

All devicesIVDReliance & recognition
Sources (2) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 1 Apr 2025

South Korea: approval fees for first-of-a-kind devices rise to about KRW 98 million

From 1 April 2025 the fee for approval of a new-development device (신개발의료기기), including technical-document review, rose from KRW 1,495,000 (online) or KRW 1,662,000 (paper) to KRW 98,430,000. The fee for a pre-review of its technical documents rose from KRW 524,000 or KRW 583,000 to KRW 55,240,000. Small and medium-sized companies can get a reduction of up to 50%. Applications filed before 1 April 2025 pay the old fees.

What to do. Budget for the new fee if your device has no Korean equivalent, and check whether you qualify for the SME reduction.

All devicesFees
Sources (1) · verified against the instrument 20 Oct 2026
China
In force
In force: 26 Mar 2025

China: innovative devices can have their clinical trial protocol pre-reviewed by CMDE

CMDE Notice 2025 No. 3 (26 March 2025) lets an applicant with an innovative device, after preclinical work and any feasibility study, ask CMDE to pre-review its clinical trial protocol through the channel for major technical questions on innovative products. The pre-review opinion is an important reference for the later technical review, and a changed protocol or device must be resubmitted. Non-innovative devices follow the published clinical evaluation guidance. CMDE Notice 2025 No. 7 (17 April 2025) then issued its working rules for reviewing applications for innovative special review and for priority review.

What to do. If your device is in, or eligible for, China's innovative special review, ask for the protocol pre-review before you start the Chinese trial.

All devicesRegistration routeClinical evidence & trials
Sources (2) · verified against the instrument 20 Oct 2026
China
In force
In force: 17 Mar 2025

China: a simpler route to make an imported Class II or III device in China

NMPA Announcement 2025 No. 30 (17 March 2025) widens the 2020 route for making an imported device in China. A foreign-invested company set up by the import registrant, or under the same actual controller, can register a Class II or III device that already holds an import certificate and make it locally. It may reuse the import dossier's summary, non-clinical (except the essential principles checklist, technical requirements and test report) and clinical evaluation sections. It needs a notarized authorization from the import registrant, a commitment that main materials and processes do not change, and a comparison of the Chinese and overseas quality systems. Imported innovative devices moved this way get priority for registration and the production license.

What to do. If you hold a China import registration and have, or plan, a Chinese entity under common control, compare this route with importing before you plan a new local registration.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
Canada
In force
In force: 5 Feb 2025

Canada: final guidance for machine-learning devices, with predetermined change control plans

Health Canada's pre-market guidance for machine-learning-enabled devices (first published 5 February 2025; current version 1 April 2026) applies to new and amended Class II to IV license applications. The cover letter should say that the device uses machine learning and whether it has a predetermined change control plan. Changes made within an authorized plan do not need a significant-change amendment but must be documented in the quality system; a change to the intended use, or to the plan itself, needs review first.

What to do. If you will retrain or update a model after launch, propose a change control plan with your first Canadian application.

Software & AISoftware & AI rulesRegistration route
Sources (2) · verified against the instrument 20 Oct 2026
South Korea
In force
In force: 24 Jan 2025

South Korea: the Digital Medical Products Act takes effect

Law No. 20139 took effect on 24 January 2025. Devices and IVDs that use AI, robotics, information and communication or other designated digital technology are licensed under it, with the Medical Devices Act applying where it is silent. Software makers and importers must obtain a decision that the software meets MFDS's quality management standard, valid three years; the Act also lets real-world data support approvals and changes, and a company selling its own stand-alone software by subscription or download does not need to register as a seller.

What to do. If you sell software or an AI-enabled device in Korea, ask your license holder how your license and the software quality conformity decision apply under the Act.

Software & AIActive (powered)IVDSoftware & AI rulesRegistration routeQMS & GMP
Sources (1) · verified against the instrument 20 Oct 2026
Argentina
In force
In force: 21 Jan 2025

Argentina: new device registration rules and risk classes, including software as a medical device

ANMAT Disposición 64/2025 (published 13 January 2025) brings Mercosur resolution GMC 25/21 into Argentine law: a new technical regulation for registering medical devices, with its own classification rules and a definition of software as a medical device. It repeals Disposición 2318/02. ANMAT applied it to initial registrations from 21 January 2025; a product whose class changes is updated at renewal. On 10 September 2026 ANMAT said that software meeting the definition, including health functions on smartwatches and wearables such as ECG, irregular-rhythm alerts and sleep-apnoea detection, must be registered.

What to do. Check your class under the new rules before renewal, and if you sell health software in Argentina, confirm whether it needs registration.

All devicesSoftware & AIClassificationRegistration routeSoftware & AI rules
Sources (3) · verified against the instrument 20 Oct 2026
European Union
In force
In force: 10 Jan 2025

European Union: warn of a supply interruption or discontinuation at least 6 months ahead

Since 10 January 2025, a manufacturer that expects to interrupt or stop supplying a device, where that could foreseeably cause serious harm to patients or public health, must tell the competent authority of the member state where it or its authorized representative is established, and the economic operators, health institutions and healthcare professionals it supplies directly. The notice is due at least 6 months before, other than in exceptional circumstances, and must give the reasons. The rule is the new Article 10a of the MDR and of the IVDR; custom-made devices are excluded under the MDR.

What to do. Add a 6-month supply-exit check to your portfolio and discontinuation decisions, and route the notice through your authorized representative.

All devicesSupply & shortagesPost-market & vigilance
Sources (2) · verified against the instrument 20 Oct 2026
China
Announced
Published: 3 Jan 2025

China: State Council reform plan for drug and device regulation sets the agenda to 2027

The State Council General Office opinion Guobanfa [2024] No. 53 (dated 30 December 2024, published 3 January 2025) sets the device reform program. It promises priority review for medical robots, brain-computer interface devices, radiotherapy and imaging equipment and high-end implants; says device clinical trial review will be cut from 60 to 30 working days; promises a simpler route for moving imported devices into Chinese production; and extends export sales certificates to every qualified manufacturer. It is a policy direction; each measure needs its own instrument, and several followed (see the entries for March 2025, December 2025 and January 2026).

What to do. Treat it as the map of what NMPA will change next, and check for the implementing instrument before relying on any one measure.

All devicesRegistration routeAdministrative
Sources (1) · verified against the instrument 20 Oct 2026
United Arab Emirates
In force
In force: 2 Jan 2025

United Arab Emirates: the federal medical products law takes effect, with a one-year window to comply

Federal Decree-Law No. 38 of 2024 on Medical Products, the Pharmacy Profession and Pharmaceutical Establishments took effect on 2 January 2025 and repealed Federal Law No. 8 of 2019. Its definition of a medical device expressly includes operating software, wearables and AI-based products. Everyone it covers had one year from that date to come into line, which by our count ended on 2 January 2026; the Cabinet may extend that period, and we have not confirmed whether it did. Regulations made under the 2019 law stay in force until replaced.

What to do. Ask your UAE registration holder whether your listings and its establishment license have been brought under the 2024 law, and treat AI and wearable products as devices in your UAE plan.

All devicesSoftware & AIAdministrativeSoftware & AI rules
Sources (1) · verified against the instrument 20 Oct 2026
Switzerland
In force
In force: 1 Jan 2025

Switzerland: longer IVD transition periods and no sell-off deadlines, from 1 January 2025

Amendments to the IvDO in force on 1 January 2025 align Switzerland with the EU's IVDR extension. For IVDs that newly need a designated body, the transition runs to December 2027 for Class D, December 2028 for Class C, and December 2029 for Class B and sterile Class A. Certificates issued under the old law remain valid until 31 December 2027. The one-year sell-off deadlines are abolished in both the MedDO and the IvDO, and the simplified designation rule in IvDO Article 87 now has no end date.

What to do. Use the Swiss IVD deadlines, which match the EU's, when planning IVDR certification for Switzerland.

IVDRegistration route
Sources (1) · verified against the instrument 20 Oct 2026
Vietnam
In force
In force: 1 Jan 2025

Vietnam: older import licenses and IVD numbers extended to 30 June 2025

Decree 04/2025/ND-CP (1 January 2025, in force on signature) let import licenses issued from 2018 to 2021, IVD circulation numbers issued from 2014 to 2019, and imports of Class C and D devices with only a published classification continue until 30 June 2025. It did this by amending Article 76 of Decree 98/2021, the transitional provisions.

What to do. Check that every product you import into Vietnam now holds a marketing authorization number of its own.

All devicesIVDImport & licensing
Sources (1) · verified against the instrument 20 Oct 2026
Mexico
In force
In force: 4 Dec 2024

Mexico: devices approved by 10 named authorities can be imported for consolidated public tenders before registration

A Health Ministry Acuerdo published on 4 December 2024, in force on publication, lets a supplier get an import permit for a device that has no Mexican registration, for consolidated public purchases run by BIRMEX and the Health Ministry. The buyers named include the Navy (SEMAR), IMSS, ISSSTE, IMSS-BIENESTAR, the National Institutes of Health and the federal referral hospitals. The Defense Ministry is not named. The device must hold an ordinary approval from the US, Canada, Japan, the UK, Brazil, Australia, Korea, Singapore, Switzerland or the European Commission. Accelerated, conditional or emergency approvals do not count. The application uses procedure COFEPRIS-01-014-A and needs a sworn letter naming the tender award. The supplier must start the Mexican registration within 10 working days of the first import. The Acuerdo has no end date, and we found no instrument repealing it as of 4 November 2026.

What to do. If you win a consolidated public tender in Mexico before your registration is through, this permit lets you deliver. Have your Mexican registration file ready, because the 10-day clock starts at the first import.

All devicesImport & licensingReliance & recognition
Sources (1) · verified against the instrument 4 Nov 2026
Read the analysis →

These summaries are for planning. Read the instrument before acting on any of them; this page is not regulatory advice. A change appears here once it has been read at source, so recent items can take a few days to arrive. "Not a device change" marks a widely reported headline whose instrument does not apply to medical devices.

Get the changes that match what you make

Meridian Trace sends each customer the week's changes for its own device types every Monday, beside its renewals and open filings, and links each change to the registrations it could affect.

Try it free →

These changes, once a month by email

What changed across our 31 markets, checked against each authority's own documents, with the dates to plan around. One email a month; unsubscribe in one click.